WO1998039335A1 - Improved methods of making cross-bridged macropolycycles - Google Patents

Improved methods of making cross-bridged macropolycycles Download PDF

Info

Publication number
WO1998039335A1
WO1998039335A1 PCT/IB1998/000299 IB9800299W WO9839335A1 WO 1998039335 A1 WO1998039335 A1 WO 1998039335A1 IB 9800299 W IB9800299 W IB 9800299W WO 9839335 A1 WO9839335 A1 WO 9839335A1
Authority
WO
WIPO (PCT)
Prior art keywords
steps
cross
bridged
carried out
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/000299
Other languages
French (fr)
Inventor
George Douglas Ii Hiler
Christopher Mark Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to DE69830574T priority Critical patent/DE69830574T2/en
Priority to JP53831198A priority patent/JP4376320B2/en
Priority to CA002282477A priority patent/CA2282477C/en
Priority to AT98904331T priority patent/ATE297928T1/en
Priority to AU62261/98A priority patent/AU6226198A/en
Priority to EP98904331A priority patent/EP0971927B1/en
Priority to BR9808657-0A priority patent/BR9808657A/en
Priority to US09/380,675 priority patent/US6225464B1/en
Publication of WO1998039335A1 publication Critical patent/WO1998039335A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Definitions

  • the present invention is in the field of macrocycle synthesis, more specifically, the synthesis of cross-bridged macrocycles having utility as proton sponges or as ligands for metal binding, especially for preparation of transition- metal containing oxidation catalysts useful, for example, in laundry detergents.
  • the present invention is also directed to the synthesis of Mn-containing complexes of cross-bridged macrocycles.
  • Macrocycles have been made in numerous ways. See, for example, "Heterocyclic compounds: Aza-crown macrocycles", J.S. Bradshaw et. al., Wiley- Interscience, 1993, which also describes a number of syntheses of such ligands. Though macrocycle synthesis is well developed in general, synthesis of cross- bridged macrocycles is not. Cross-bridged macrocycle synthesis is rare and difficult, and involves multiple steps and unpleasant solvents (DMF, acetonitrile, or the like).
  • Cross-bridging i.e., bridging across nonadjacent nitrogens, of a known macrocycle, cyclam (1,4,8,11-tetraazacyclotetradecane), is known in limited context. It is, for example, described by Weisman et al, J. Amer. Chem. Soc. (1990), 112(23), 8604-8605. More particularly. Weisman et al., Chem. Commun.. (1996), pp.
  • Weisman also provides a synthesis method for a cross-bridged cyclam which uses three steps, two of which use acetonitrile as solvent. These steps are (1) reaction of a parent macrocycle with glyoxal to form a bisaminal and (2) quaternization of the bisaminal with methyl iodide, to form a dimethylated bisaminal diiodide. A further step, (3), reduction of the diquatemary intermediate produced in the second step, is required to make the desired product. This step uses ethanol as solvent. There is an apparent requirement to conduct the synthesis at relatively high dilution, which is commercially unattractive.
  • current syntheses have one or more of the following limitations: (a) they use relatively environmentally undesirable solvents, such as acetonitrile; (b) they may incorporate "high-dilution” steps, increasing solvent consumption; (c) they require switching from one solvent to another in different stages of manufacture; increasing cost and complexity further, and (d) they are wasteful in calling for large excesses of materials such as alkyl halides and/or reducing agents.
  • Figure 1 is a process outline presented for purposes of orienting in the present process.
  • the present process has a series of essential steps, marked (A), (B), and (C) in Figure 1 ; these are single steps, they are marked in bold, and they are conducted in sequence.
  • the process may also contain further operations, such as (D), (E) or (F), any one of which operations may comprise one or more steps and which may be used to work up the crude product of the essential process steps; the product may then be sold or used for further conversions, for example in one or more steps to make a useful transition-metal bleach catalyst (G).
  • the process desirably incorporates solvent recycle from one or more of (A), (B), (C) and (when used), (D).
  • FIG. 2 is also a process outline for a preferred embodiment of the invention.
  • the bisaminal in step (A) is formed from a relatively inexpensive acyclic amine.
  • step (B) the bisaminal is converted to a specific diquatemary derivative.
  • step (C) this is reduced.
  • step (D) reducing agent and solvent are separated in one or more separation operations.
  • step (E) which in general is optional but is preferred if there is any appreciable amount of reducing agent left after step D, residual hydride is removed.
  • step (F) the product, a cross- bridged macrocycle suitable for forming transition metal complexes which are useful bleach catalysts in detergents, is isolated.
  • step (G) optionally including one or more purification steps on the final product, transition metal complex of the cross- bridged macrocycle is formed.
  • (A) - (G) occur in the indicated sequence.
  • the present invention relates to a method for preparing a cross- bridged macropolycycle, preferably a cross-bridged tetraazamacrocycle, comprising a series of steps, preferably three steps in sequence, of derivatizing cyclam or a particular acyclic tetraamine, wherein said series of steps is carried out using in common in each of said steps, substantially one solvent system.
  • said solvent system is an alcoholic solvent system; more preferably the solvent system comprises from about 60% to 100% of a C1-C4 alcohol, such as methanol, ethanol, n-propanol, 2-propanol, n-butanol, t-butanol, or mixtures thereof; ethanol and 2- propanol are preferred. More generally, and in preferred embodiments, mixtures of lower alcohol and, for example, from about 0.1% to about 70% water, more typically from about 1% to about 40% water, can also be useful and economic. In a highly preferred embodiment, said solvent system is substantially ethanol or mixtures thereof with water. The solvent system is preferably completely free from acetonitrile.
  • a C1-C4 alcohol such as methanol, ethanol, n-propanol, 2-propanol, n-butanol, t-butanol, or mixtures thereof; ethanol and 2- propanol are preferred.
  • the invention secures a "one-pot” method for making the cross-bridged macrocycle.
  • "One pot” methods in general are highly advantageous - they permit reduced investment in manufacturing steps and equipment. Such an advantage is secured by the present process, which is simple, economic, and improved in terms of environmental acceptability.
  • the invention further relates to a method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of quatemizing an intermediate using a quatemizing agent, wherein said step is carried out using a minimized amount of said quatemizing agent.
  • the invention further relates to a method for preparing a cross-bridged macropolycycle comprising an alternate first step of forming a bisaminal by (i) reacting a suitable acyclic tetraamine with glyoxal to form a tricyclic macropolycycle and (ii) converting the tricyclic compound to the bisaminal by reacting it with a dihaloalkane, preferably and more generally a compound selected from the group consisting of ⁇ , ⁇ u-dichloroalkanes, ⁇ ,t ⁇ -dibromooalkanes, ⁇ , ⁇ - diiodoalkanes, ⁇ , ⁇ - ditosylalkanes and mixtures thereof, more preferably ⁇ , ⁇ jj- dibromooalkanes or ⁇ , ⁇ u- ditosylalkanes.
  • a dihaloalkane preferably and more generally a compound selected from the group consisting of ⁇ , ⁇ u-dichlor
  • the method of the invention has a second step which is carried out using less than about fifteen-fold of said quatemizing agent; typically, levels of about five-fold to about 10-fold of said quatemizing agent can be practiced.
  • "Reagents” herein are materials, such as the glyoxal of step A, the quatemizing agent of step B, or the reducing agent of step C, which are chemically reacted with a macrocycle. Ratios of reagents herein, unless otherwise noted, are expressed on a molar basis; thus the term "three-fold" with respect to an amount of reagent over an amount of macrocycle means that the amount of reagent is three times the number of moles of the macrocycle it is being used to functionalize.
  • a suitable quatemizing agent is methyl iodide, but the present method contains the further improvement of providing alternative, more environmentally attractive quatemizing agents further illustrated hereinafter.
  • the present invention encompasses a method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of reducing a diquatemized intermediate, wherein said step is carried out using a minimized amount of reducing agent.
  • said step is carried out using an amount of less than about fifteen- fold of said reducing agent. More typically, the reducing agent is from about 2.5 - fold to about 10-fold the amount of macrocycle, on a molar basis.
  • any suitable reducing agent both catalytic and non-catalytic
  • a tube reactor containing materials for catalytic hydrogenation providing a locally high concentration of reducing species can be used.
  • a preferred group of reducing agents herein, especially for the one-pot process are non-catalytic reducing agents.
  • Zn/HCl is a well- known reducing agent having the advantage that it can be used in water, and can be used herein.
  • Preferred non-catalytic reducing agents are hydride compounds; more preferred are hydride compounds which can be used in wet (water-containing) systems.
  • Preferred hydride compounds are borohydride and borane.
  • Suitable borohydride compounds are selected from sodium borohydride and potassium borohydride. Less preferably, lithium borohydride can be used.
  • pH may be adjusted using small amounts of alkali to limit wasteful decomposition and release of hydrogen from the hydride.
  • 2-propanol and t-butanol have known advantages of producing less wasteful hydrogen evolution than, say, methanol or ethanol.
  • the invention also encompasses a method in which sodium ion is substantially absent.
  • the terms "substantially absent” or “substantially free” in connection with a material herein mean that the material is not deliberately added, though adventitious amounts are permissible. Surprisingly, sodium ion, though usable, has some adverse effect on the method, so sodium ion, other than adventitious amounts, are excluded in certain preferred embodiments.
  • the present invention relates to a method having each of the foregoing steps, in sequence.
  • the steps can be carried out in "one pot" to secure the maximum advantages.
  • the practitioner may choose not to secure the maximum benefits, for example if the different steps are carried out at multiple manufacturing locations, or for other reasons, such as a desire to use a specialized hydrogenation reactor in the third step. In this instance, practitioners may still avail themselves of the improvements in any one or two of the individual steps in any one manufacturing location or facility.
  • the invention further relates to the method described hereinabove which is carried out in the absence of any step of vacuum distilling an intermediate; and to a method which is carried out at low temperatures, especially wherein said quatemization and reduction steps are carried out at the low temperatures of from about ambient temperature to about 50°C, more preferably lower than about 50°C.
  • all steps are carried out at concentrations of the reactants of about 7% or higher, by weight in total of the sum of reactants plus solvent; preferably, the concentrations of the reactants exceeds about 15% in total of the sum of reactants plus solvent. This permits the use of smaller and less costly manufacturing plant and the use of lower, safer amounts of flammable materials.
  • the invention secures numerous advantages in relation to the manufacture of cross-bridged macrocycles, as non-limitingly illustrated by cross-bridged cyclam derivatives. Indeed the advantages of the present method make a substantial difference to the possibility of commercially producing cross-bridged macrocycles for the useful purposes outlined in the background.
  • the present invention relates to a method for producing a complex of Mn with a cross-bridged macrocyclic ligand.
  • Said method comprises preparing said complex, preferably under strictly oxygen and hydroxyl-free (ideally completely anhydrous) conditions by reaction of MnC-2 with a cross-bridged macropolycycle.
  • the present invention involves a process or method having three essential steps, (A), (B) and (C) as shown in Figure 1, optionally followed by additional steps.
  • Step (A) is non-limitingly illustrated as follows:
  • the above step the yield of which is from about 85% to 100%, typically near quantitative (100%), can be carried out using ethanol as a solvent and a concentration of reactants of 7%.
  • the reagent, glyoxal can be used pure or undiluted, or as a solution, for example and aqueous solution. More generally, in this step, the concentration of reactants by weight in the sum of all solvents including water, if present, is in the range from about 7% to about 20%, or higher. Thus, cyclam is slurried at 7% in ethanol.
  • the slurry is stirred using any convenient stirring means, such as a mechanically driven paddle stirrer.
  • the above depicted co- reactant, glyoxal is dripped in, preferably keeping the temperature below about 35 ° C. More generally, the temperature can be in the range from about 10 °C to about 40 °C.
  • the addition reaction is over, typically within one hour, more generally in from about 10 min. to about 3 hours, it is found to be quantitative by any suitable means, for example C-13 NMR.
  • Step (A) and all other steps herein can in general be conducted at atmospheric pressure, or overpressures if desired.
  • the term "overpressures" herein means pressures greater than atmospheric.
  • any step or steps can be conducted at overpressures, for example to contain volatile solvents or reagents above their normal boiling-points.
  • the cis-tetracycle (product of step (A)) is not isolated; rather it is kept in the reaction solvent and the process proceeds to step (B).
  • the cis-tetracycle is prepared using the following scheme:
  • Step (A) This alternate procedure is referred to as alternate Step (A), comprising step A (i) and step A(ii) as shown.
  • a suitable tetramine, N,N'-bis-(2- aminoethyl)-l,3-propanediamine is reacted with glyoxal, typically about 1-10 molar equivalents, preferably from about 0.8 to about 1.5 molar equivalents, very suitably 1 molar equivalent, in a solvent, ethanol being preferred, at temperatures in the range from about 0 to 100°C, more preferably 0 to 25°C, for a period of from about 1 min. to about 7 days, preferably from about 15 min. to about 2 hours.
  • the intermediate product a tricycle of the shown structure, can either be isolated by distillation or can be further reacted to form the cis-tetracycle without changing reactor.
  • the conversion of the tricycle to the cis-tetracycle can suitably be conducted using a 1,3- dihalopropane, typically 1,3-dibromopropane, or the ditosylate of 1,3-propanediol can alternatively be used.
  • Suitable solvents are ethanol (ideal for one-pot purposes) or acetonitrile.
  • a base is used to prevent the tricyclic amine reactant from protonating as the reaction continues.
  • Suitable bases can vary widely and can include potassium carbonate or organic bases which are resistant to alkylation, such as di- isopropylethylamine (K ⁇ enig's base).
  • the amount of the base is typically from 1-10 equivalents, preferably from about 2 equivalents to about 6 equivalents.
  • the reaction temperature is in the range from about 0 to 100°C, more preferably 0 to 30°C, for a period of from about 15 min. to about 7 days, preferably from about 30 min. to about 2 hours.
  • workup can vary.
  • the reaction mixture is filtered to remove solid base and the filtrate is evaporated to yield the cis-tetracycle as a solid.
  • an organic base the solvent is evaporated and the evaporate is distilled.
  • this material is quatemized, as non-limitingly illustrated using alkyl halide (CH3I) in the reaction scheme.
  • CH3I alkyl halide
  • Such a step has a yield of about 80%), or higher. Yields of 80% can typically be achieved. More generally, in this step, the concentration of reactants by weight in the sum of all solvents including water, if present, is in the range from about 7% to about 20%, or higher.
  • step (B) is thereby modified to allow access to additional macrocyclic compounds as alternate products of the present process.
  • the temperature is maintained in the general range from about 10 °C to about 38 °C, more preferably from about 15 °C to about 30 °C.
  • monoquatemized intermediate not shown in the reaction sequence
  • undesired byproducts such as a triquatemized derivative (also not shown in the reaction sequence).
  • mono-quat intermediate is precipitated; but in order to maximize reaction rate, measures are taken to keep the particle size small and the surface area of intermediate mono-quat as high as possible.
  • reaction time in step (B) is a period of from about 0.5 hours to 72 hours. Typical reaction times when not taking any special measures to accelerate reaction are from about 24 hours to about 72 hours, for example about 48 hours.
  • the monoquat intermediate referred to supra usually begins to separate from solution about 1 hour after addition of methyl iodide.
  • the reaction can desirably be monitored, for example by C-13 NMR. When reaction to form diquat is complete the ethanol can, if desired, be siphoned off (this is convenient, especially for the one-pot variation of the present process).
  • Solvents are desirably recycled in this and all other steps where recycle is possible.
  • Recycle can be by any convenient means, for example by means of conventional distillation apparatus.
  • Solid product of step (B) can be washed with ethanol, typically several times, to remove excess methyl iodide.
  • Step (B) can be conducted at atmospheric pressure; however, any suitable overpressure may be quite desirable when the quatemizing agent is low-boiling.
  • alkyl halides such as chloromethane, or, more generally, other quatemizing agents such as dimethyl sulfate or methyltosylate, can be substituted in the above procedure.
  • quatemizing agents such as dimethyl sulfate or methyltosylate
  • the desired product of this step is derived from an initially-formed and practically insoluble mono quat.
  • the di-quat compound is even more insoluble than the mono-quat.
  • it might have been thought desirable to solublize the mono-quat in order to accelerate the reaction, it might have been thought desirable to solublize the mono-quat; however, excessive solubilization of mono-quat intermediate, which, in turn, may lead to undesirable solubilization of diquat, is avoided in preferred embodiments of the present process, thereby limiting formation of undesired, tri quat byproduct.
  • Step fC is non-limitin ⁇ giy illustrated as follows:
  • Step (C) is a reduction step, having typical yield of 80% or higher.
  • the solids from the diquat reaction of step (B) are dissolved in water and ethanol is added to make a 80%) ethanol solution; the final concentration of the diquat is 20 % by weight in the total of solvents (for example 81 :19 ethanohwater by weight).
  • C1-C4 lower alcohol may be used in all of steps (A), (B) and (C) and in step (C) a preferred solvent system comprises from about 50 % to about 95% lower alcohol and the balance water.
  • An excess, preferably from about 3 to about 10, for example, 6, equivalents of sodium borohydride are added slowly, with stirring using any convenient means.
  • the borohydride may, for example, by slurried in a portion of solvent and added as the slurry, if it is desired to avoid solids-handling and obtain excellent control of the addition.
  • the reaction becomes very exothermic. Temperature is maintained in the range from about 0 °C to about 80 °C, more preferably from about 20 °C to about 50 °, using cooling means such as an ice bath if needed.
  • the reaction mixture is stirred, generally from about 1.5-72 hours, typically up to ethanol reflux.
  • reaction times at relatively lower temperatures are safest in this step (C) and safety may be further enhanced by passage of an inert gas, such as nitrogen, to flush out hydrogen, especially from the reactor headspace.
  • an inert gas such as nitrogen
  • Suitable reducing agents herein include the borohydrides, but preferably, nonsodium salt forms. Reaction is optionally monitored by ion spray mass spec.
  • step (C) any of a range of alternative steps or combination of steps may follow step (C).
  • a step identified as (E) in Fig. 1. can be used.
  • the pH is adjusted to between 1 and 2 with 37% HC1 (slow addition of acid is required, reaction is very exothermic) and the reaction solution is concentrated at reduced pressure to a thick slurry.
  • the thick slurry is then made basic (pH>14), for example with 8M KOH.
  • product can be extracted with toluene and subjected to further purification, such as by distillation.
  • Preferred embodiments of the instant invention include those not having vacuum distillation as a requirement.
  • a preferred workup sequence comprises the steps of (D) (i) reducing agent removal, for example by simple filtration, (D) (ii) solvent removal, for example by evaporation, (E) residual hydride removal, for example by using acid-treatment followed by base treatment as defined supra, and (F) separation of the desired cross-bridged macrocycle, for example by distillation.
  • the product of step (F) is used in subsequent step (G) to form a transition-metal complex, for example a complex of manganese.
  • a preferred product of the present process is 5,12- dimethyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane.
  • This product is obtained when cyclam is used as the parent macrocycle.
  • the invention methods should not be taken as limited to this particular material, as it is equally amenable to the preparation of any one of a wide range of cross-bridged macrocycles.
  • any one or more substituent moieties such as alkyl or alkaryl moieties, may be present, covalently attached to the parent macrocycle used in step (A).
  • other macrocycles can be made by the process through the variation of adding methyl halide along with another alkyl halide in step (B).
  • 5-n- butyl-12-methyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane can be prepared by the present process by use of a mixture of 1-iodobutane and methyl iodide, very preferably by consecutive reaction first of an equivalent of iodobutane then an equivalent of methyl iodide, in step (B).
  • the present process can be used to prepare the cross-bridged macrocycle 5-benzyl-12-methyl-l,5,8,12-tetraaza- bicyclo[6.6.2]hexadecane, simply by use of the variation of adding methyl iodide and benzyl bromide, instead of only methyl iodide, in step (B). All of these cross- bridged macrocycles can thus be prepared using the desirable features of the invention, for example their independence from use of dimethylformamide or acetonitrile and their improved yields, especially in step (A), all to great economic advantage.
  • the macrocyclic ligand is reacted directly with manganese as an inorganic salt free of organic ligands such as pyridine, to form useful transition-metal complexes.
  • the source of manganese chloride can include analytical and technical grades, and can be fully anhydrous or only partly anhydrous.
  • Manganese chloride is commercially available from Chemetals Corp., Spectrum Bulk Chemicals Corp., American International Chemical Inc., Barker Industries Inc., and Mineral Research and Development Corp. As noted in Kirk-Othmer's Encyclopedia, manganese chloride can be prepared from the carbonate or oxide by dissolving it in hydrochloric acid. Heavy-metal contamination can be removed by precipitation through the addition of manganese carbonate which increases the pH.
  • Anhydrous manganese chloride can also be made by reaction of manganese metal, carbonate or oxide, and dry hydrochloric acid.
  • Manganese chloride is manufactured by Chemetals Corp., using a process in which manganese(II) oxide is leached with hydrochloric acid.
  • Manganese carbonate is added after completion of the initial reaction to precipitate the heavy-metal impurities.
  • the solution is concentrated and cooled and the manganese chloride is isolated.
  • step (A) it is an advantage of the present invention to be able to proceed all the way from step (A) to step (G) (see Figure 1 ) without having to make an intermediate complex of manganese with an organic ligand.
  • high-purity manganese chloride grades especially those which are totally anhydrous, work very well in the instant invention, it is a further advantage to be able to use grades such as the 98%+ grade and the 99% grade which are not totally anhydrous and are available at substantially lower cost.
  • the macropolycyclic ligands herein can be reacted with manganese chloride in any convenient manner. See Examples 10 and 11 , in each, see (b), Method (II). Any variation of such non-limiting illustrations of the process for step (G) of the instant invention are encompassed herein; for example, argon or nitrogen and degassing procedures while they can be useful for best results can be dispensed with, especially in larger-scale commercial operation; likewise rotary evaporation and other laboratory-scale procedures can readily be scaled up to commercial-scale equipment. Any convenient organic solvent can be used, for example acetonitrile, though other solvents are also possible.
  • step (G) conversion of macrocyclic ligand to transition-metal complex is conducted at temperatures from about ambient to about 100°C, preferably from about 40°C to about 80°C; and no water is deliberately added to the solvent system. Pressures are typically atmospheric, though higher pressures may be used if desired, for example to help contain volatile solvents.
  • the present invention is further non-limitingly illustrated by the following examples.
  • Step A Reagents: Parent macrocycle, MW 506.21, 10 moles
  • Step B reagents: Product of step A and Methyl Iodide
  • Step C reagents: Product of Step B and Sodium Borohydride.
  • EXAMPLE 2 The method of Example 1 is repeated, except that an equal number of moles of dimethylsulfate replaces the methyl iodide.
  • EXAMPLE 3 The method of Example 1 is repeated, except that potassium borohydride replaces sodium borohydride in equimolar amount.
  • Example 4 The method of Example 1 is repeated, except that the solvent system is ethanol-only in steps A and B.
  • Example 6 The method of Example 1 is repeated, except that steps A and B are carried out in the original reaction vessel while step C is conducted in a second reaction vessel. The first reaction vessel is then freed from the requirement to handle hydrogen evolution.
  • EXAMPLE 7 The method of Example 1 is repeated, except that the reagent ratio to macrocycle is 1.1 -fold, 3-fold and 3-fold in steps (A), (B) and (C) respectively. (In the terms given in the Table of Example 1, column 5 numbers are 1.1 :1, 3:1 and 3:1). In another variation, a mixture of methyl iodide and 1-iodobutane replaces the methyl iodide of Example 1 , demonstrating that the present process can be used to prepare different kinds of cross-bridged macrocycles.
  • EXAMPLE 8 Purification of the product of Example 1. (Conventional) . Aqueous phase crude product from Example 1 is extracted with 5 portions of toluene. The extracts are combined and evaporated. The product is vacuum distilled at 100 C, 0.1 mm
  • EXAMPLE 9 This example further illustrates the conversion of product of Example 1, after purification, to a useful bleach catalyst by the present invention process.
  • Reagents according to the present invention are in anhydrous form.
  • Product of Example 1 after conventional purification (for example distillation) is slurried in a 10%) solution of acetonitrile and degassed with argon.
  • Anhydrous MnCl2 (more economically, 98%> or 99% grade) is then added and the reaction refluxed under argon for 4 hours. Reaction can be monitored qualitatively by color; pale blue being positive indication reaction is proceeding normally - any ingress of air may cause darkening.
  • the reaction mixture is then filtered hot through a glass micro fiber filter and, if desired, again through a 0.2 micron filter. Filtrate is then concentrated at reduced pressure to dryness and the solids suspended and washed 5X in 2 volumes of toluene and then filtered and dried.
  • This example also further illustrates the conversion of product of Example 1, after purification, to a useful bleach catalyst.
  • Bcyclam (5,12-dimethyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane) , is the product of the process of the invention.
  • Bcyclam (1.00 g., 3.93 mmol) is dissolved in dry CH3CN (35 mL, distilled from CaH2). The solution is then evacuated at 15 mm until the CH3CN begins to boil. The flask is then brought to atmospheric pressure with Ar. This degassing procedure is repeated 4 times.
  • Mn(pyridine)2Cl2 (1.12 g., 3.93 mmol), synthesized according to the literature procedure of H. T. Witteveen et al., J. Inorg. Nucl. Chem..
  • This filtrate is evaporated to dryness using a rotoevaporator.
  • the resulting tan solid is dried overnight at 0.05 mm at room temperature.
  • the solid is suspended in toluene (100 mL) and heated to reflux.
  • the toluene is decanted off and the procedure is repeated with another 100 mL of toluene.
  • the balance of the toluene is removed using a rotoevaporator. After drying overnight at.05 mm at room temperature, 31.75 g. of a light blue solid product is collected, 93.5% yield.
  • 1 -Iodobutane (24.84 g., 135 mmol) is added to the stirred solution under Ar. The solution is stirred at room temperature for 5 days. 4-Iodobutane (12.42 g., 67.5 mmol) is added and the solution is stirred an additional 5 days at RT. Under these conditions, I is fully mono-alkylated with 1 -iodobutane as shown by 13C_NMR.. Methyl iodide (26.5 g, 187 mmol) is added and the solution is stirred at room temperature for an additional 5 days. The reaction is filtered using Whatman #4 paper and vacuum filtration. A white solid, II, is collected (6.05 g., 82%).
  • the white residue is dissolved in sodium hydroxide (500 mL, OON). This solution is extracted with toluene (2 x 150 mL). The toluene layers are combined and dried with sodium sulfate. After removal of the sodium sulfate using filtration, the toluene is evaporated to dryness using a rotoevaporator. The resulting oil is dried at room temperature under high vacuum (0.05 mm) ovemight. A colorless oil results 2.95 g., 90%. This oil (2.10 g.) is distilled using a short path distillation apparatus (still head temperature 115 C at 0.05 mm). Yield: 2.00 g.
  • the filtrate is a light tan color. This filtrate is evaporated to dryness using a rotoevaporator. The resulting white solid is suspended in toluene (50 mL) and heated to reflux. The toluene is decanted off and the procedure is repeated with another 100 mL of toluene. The balance of the toluene is removed using a rotoevaporator. After drying ovemight at 0.05 mm, RT, 2.4 g. a light blue solid (III) results, 88% yield. Ion Spray Mass Spectroscopy shows one major peak at 396 mu corresponding to [Mn(C4-Bcyclam)(formate)] + .
  • the macrocycle is synthesized similarly to the C4-Bcyclam synthesis described above, except that benzyl bromide is used in place of the 1 -iodobutane in step (B) of the instant process.
  • This ligand is synthesized similarly to the C4-Bcyclam synthesis described above except that 1-iodooctane is used in place of the 1 -iodobutane. Mass Spec. (MH+, 353).
  • This complex is made similarly to the [Mn(C4-Bcyclam)Cl2] synthesis described above except that Cg-Bcyclam is used in place of the C4-Bcyclam.
  • the H2-Bcyclam is synthesized similarly to the C4-Bcyclam synthesis described above except that benzyl bromide is used in place of the 1 -iodobutane and the methyl iodide.
  • the benzyl groups are removed by catalytic hydrogenation.
  • the resulting 5,12-dibenzyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane and 10% Pd on charcoal is dissolved in 85% acetic acid.
  • This solution is stirred 3 days at room temperature under 1 atm. of hydrogen gas.
  • the solution is filtered though a 0.2 micron filter under vacuum. After evaporation of solvent using a rotary evaporator, the product is obtained as a colorless oil. Yield: 90 + %>.
  • This product may be further purified by recrystallization from an ethanol/diethylether mixture combined with cooling at 0°C ovemight to yield a white crystalline solid.
  • Bis(pyridine)manganese (II) chloride is synthesized according to the literature procedure of H. T. Witteveen et al., J Inorg. Nucl. Chem., 1974, 3_6, 1535.
  • the ligand L ⁇ (1.24g, 3.5mmol), triethylamine(0.35g, 3.5mmol) and sodium hexafluorophosphate (0.588g, 3.5mmol) are dissolved in pyridine (12ml). To this is added bis(pyridine)manganese (II) chloride and the reaction is stirred ovemight. The reaction is then filtered to remove a white solid. This solid is washed with acetonitrile until the washings are no longer colored and then the combined organic filtrates are evaporated under reduced pressure. The residue is dissolved in the minimum amount of acetonitrile and allowed to evaporate ovemight to produce bright red crystals. Yield: 0.8g (39%). Anal. Calcd.
  • Manganese (II) trifluoromethanesulfonate (0.883g, 2.5mmol) is dissolved in acetonitrile (5ml). This is added to a solution of the ligand Li (0.878g, 2.5mmol) and triethylamine (0.25g, 2.5mmol) in acetonitrile (5ml). This is then heated for two hours before filtering and then after cooling removal of the solvent under reduced pressure. The residue is dissolved in a minimum amount of acetonitrile and left to evaporate slowly to yield orange crystals. Yield 1.06g (60%). Anal. Calc. for Mn 1 C 2 3H29N 5 S 2 F 6 O 6 : C, 39.20; H, 4.15 and N, 9.95.
  • Iron (II) trifluoromethanesulfonate is prepared in situ by the literature procedure Tait and Busch, Inorg. Synth.. 1978, XVIII, 7.
  • the metal complexes can be used in detergents, for example by adding about 0.05%) of complex to a granular detergent containing 10% sodium perborate, to improve bleaching.
  • the state of purity of the transition-metal oxidation catalyst of Example 9 can vary, provided that any impurities, such as byproducts of the synthesis, free ligand(s), unreacted transition-metal salt precursors, colloidal organic or inorganic particles, and the like, are not present in amounts which substantially decrease the utility of the transition-metal oxidation catalyst. It has been discovered to be desirable that the transition-metal oxidation catalyst should be purified. This can be done using any suitable means, such that the catalyst does not excessively consume available oxygen (AvO). Excessive AvO consumption is defined as including any instance of exponential decrease in AvO levels of bleaching, oxidizing or catalyzing solutions with time at 20-40°C.
  • Preferred transition-metal oxidation catalysts when placed into dilute aqueous buffered alkaline solution at a pH of about 9 (carbonate/bicarbonate buffer) at temperatures of about 40°C, have a relatively steady decrease in AvO levels with time; in preferred cases, this rate of decrease is linear or approximately linear.
  • AvO slope a graph of %AvO vs. time (in sec.)
  • a preferred Mn(II) oxidation catalyst has an AvO slope of from about -0.0140 to about -0.0182; in contrast, a somewhat less preferred transition metal oxidation catalyst has an AvO slope of - 0.0286.
  • Preferred methods for determining AvO consumption in aqueous solutions of transition metal oxidation catalysts herein include the well-known iodometric method or its variants, such as methods commonly applied for hydrogen peroxide. See, for example, Organic Peroxides, Vol. 2., D. Swem (Ed.,), Wiley-Interscience, New York, 1971, for example the table at p. 585 and references therein including P.D. Bartlett and R. Altscul, J. Amer. Chem. Soc, 67, 812 (1945) and W.E. Cass, J. Amer. Chem. Soc, 68, 1976 (1946). Accelerators such as ammonium molybdate can be used.
  • the general procedure used herein is to prepare an aqueous solution of catalyst and hydrogen peroxide in a mild alkaline buffer, for example carbonate/bicarbonate at pH 9, and to monitor the consumption of hydrogen peroxide by periodic removal of aliquots of the solution which are "stopped” from further loss of hydrogen peroxide by acidification using glacial acetic acid, preferably with chilling (ice). These aliquots can then be analyzed by reaction with potassium iodide, optionally but sometimes preferably using ammonium molybdate (especially low-impurity molybdate, see for example U.S. 4,596,701) to accelerate complete reaction, followed by back-titratation using sodium thiosulfate.
  • a mild alkaline buffer for example carbonate/bicarbonate at pH 9
  • ammonium molybdate especially low-impurity molybdate, see for example U.S. 4,596,701
  • thermometric procedures such as thermometric procedures, potential buffer methods (Ishibashi et al., Anal. Chim. Acta (1992), 261(1-2), 405- 10) or photometric procedures for determination of hydrogen peroxide (EP 485,000 A2, May 13, 1992).
  • Variations of methods permitting fractional determinations, for example of peracetic acid and hydrogen peroxide, in presence or absence of the instant transition-metal oxidation catalysts are also useful; see, for example JP 92- 303215, Oct. 16, 1992.
  • laundry and cleaning compositions incorporating transition-metal oxidation catalysts which have been purified to the extent of having a differential AvO loss reduction , relative to the untreated catalyst, of at least about 10 %> (units here are dimensionless since they represent the ratio of the AvO slope of the treated transition-metal oxidation catalyst over the AvO slope for the untreated transition metal oxidation catalyst - effectively a ratio of AvO's).
  • the AvO slope is improved by purification so as to bring it into the above-identified preferred ranges.
  • One such process is any process having a step of treating the transition-metal oxidation catalyst, as prepared, by extracting the transition-metal oxidation catalyst, in solid form, with an aromatic hydrocarbon solvent; suitable solvents are oxidation- stable under conditions of use and include benzene and toluene, preferably toluene. Surprisingly, toluene extraction can measurably improve the AvO slope (see disclosure hereinabove).
  • Another process which can be used to improve the AvO slope of the transition metal oxidation catalyst is to filter a solution thereof using any suitable filtration means for removing small or colloidal particles.
  • suitable filtration means include the use of fine-pore filters; centrifugation; or coagulation of the colloidal solids.
  • a full procedure for purifying a transition-metal oxidation catalyst herein can include: (a) dissolving the transition-metal oxidation catalyst, as prepared, in hot acetonitrile:
  • step (e) washing the solids of step (d) with toluene, for example five times using toluene in an amount which is double the volume of the oxidation catalyst solids;
  • Recrystallization for example of Mn(II) Bcyclam chloride transition-metal oxidation catalyst, can be done from hot acetonitrile. Recrystallization can have its disadvantages, for example it may on occasion be more costly.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Multi-Process Working Machines And Systems (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Small-Scale Networks (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Improved synthesis of a macropolycycle, more particularly, of a cross-bridged tetraazamacrocycle.

Description

IMPROVED METHODS OF MAKING CROSS-BRIDGED MACROPOLYCYCLES
TECHNICAL FIELD
The present invention is in the field of macrocycle synthesis, more specifically, the synthesis of cross-bridged macrocycles having utility as proton sponges or as ligands for metal binding, especially for preparation of transition- metal containing oxidation catalysts useful, for example, in laundry detergents. The present invention is also directed to the synthesis of Mn-containing complexes of cross-bridged macrocycles.
BACKGROUND OF THE INVENTION
Whereas macrocyclic chemistry, in general, is highly developed, the art of manufacturing cross-bridged macrocycles is new. Certain such macrocycles, such as cross-bridged derivatives of cyclam, have only recently been synthesized in small amounts, and commercial processes are not known. It would be highly desirable to have such processes, since cross-bridged macrocycles have unique advantages as proton sponges or when used as ligands in the catalysis of bleaching.
Macrocycles have been made in numerous ways. See, for example, "Heterocyclic compounds: Aza-crown macrocycles", J.S. Bradshaw et. al., Wiley- Interscience, 1993, which also describes a number of syntheses of such ligands. Though macrocycle synthesis is well developed in general, synthesis of cross- bridged macrocycles is not. Cross-bridged macrocycle synthesis is rare and difficult, and involves multiple steps and unpleasant solvents (DMF, acetonitrile, or the like).
Cross-bridging, i.e., bridging across nonadjacent nitrogens, of a known macrocycle, cyclam (1,4,8,11-tetraazacyclotetradecane), is known in limited context. It is, for example, described by Weisman et al, J. Amer. Chem. Soc. (1990), 112(23), 8604-8605. More particularly. Weisman et al., Chem. Commun.. (1996), pp. 947-948, describe a range of assertedly new cross-bridged tetraamine ligands which are bicyclo[6.6.2], [6.5.2], and [5.5.2] systems, and their complexation to Cu(II) and Ni(II), demonstrating that the ligands coordinate the metals in a cleft. Specific complexes reported include those of the ligands 1.1 :
Figure imgf000004_0001
1.1 in which A is hydrogen or benzyl and (a) m=n=l; or (b) m=l and n=0; or (c) m=n=0, including a Cu(II)chloride complex of the ligand having A= H and m=n=l; Cu(II) perchlorate complexes where A=H and m=n=:l or m=n=0; a Cu(II)chloride complex of the ligand having A= benzyl and m=n=0; and a Ni(II)bromide complex of the ligand having A=H and m=n=l . This handful of complexes appears to be the total of those known wherein the bridging is not across "adjacent" nitrogens.
Weisman also provides a synthesis method for a cross-bridged cyclam which uses three steps, two of which use acetonitrile as solvent. These steps are (1) reaction of a parent macrocycle with glyoxal to form a bisaminal and (2) quaternization of the bisaminal with methyl iodide, to form a dimethylated bisaminal diiodide. A further step, (3), reduction of the diquatemary intermediate produced in the second step, is required to make the desired product. This step uses ethanol as solvent. There is an apparent requirement to conduct the synthesis at relatively high dilution, which is commercially unattractive. Yields are borderline for commercial utility ( only 80% and 85% in the first and second steps, respectively.) In view of the desirable properties of cross-bridged macrocycles as ligands and the limitations of the existing method of making such a macrocycle, there is a clear need and desire for improvement in the synthesis of such cross-bridged macrocycles.
To summarize, current syntheses have one or more of the following limitations: (a) they use relatively environmentally undesirable solvents, such as acetonitrile; (b) they may incorporate "high-dilution" steps, increasing solvent consumption; (c) they require switching from one solvent to another in different stages of manufacture; increasing cost and complexity further, and (d) they are wasteful in calling for large excesses of materials such as alkyl halides and/or reducing agents.
Accordingly, it would be highly desirable to improve the synthesis of cross- bridged macrocycles, and in particular, methods for making cross-bridged derivatives of cyclam, and to provide methods for synthesizing Mn-containing complexes with cross-bridged macrocyclic ligands. These and other improvements are secured herein, as will be seen from the following disclosure.
BACKGROUND ART
See documents cited in the background. Also, Tabushi and co-workers, cited in Bradshaw et al., supra, make use of ethanol as a solvent for preparing a tetraazamacrocycle by dimerization. However, the macrocycle is not cross-bridged and the method described is not capable of forming a cross-bridged macrocycle. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a process outline presented for purposes of orienting in the present process. In a preferred embodiment, the present process has a series of essential steps, marked (A), (B), and (C) in Figure 1 ; these are single steps, they are marked in bold, and they are conducted in sequence. The process may also contain further operations, such as (D), (E) or (F), any one of which operations may comprise one or more steps and which may be used to work up the crude product of the essential process steps; the product may then be sold or used for further conversions, for example in one or more steps to make a useful transition-metal bleach catalyst (G). The process desirably incorporates solvent recycle from one or more of (A), (B), (C) and (when used), (D).
Figure 2 is also a process outline for a preferred embodiment of the invention. In this process, the bisaminal in step (A) is formed from a relatively inexpensive acyclic amine. In step (B) the bisaminal is converted to a specific diquatemary derivative. In step (C) this is reduced. In step (D), reducing agent and solvent are separated in one or more separation operations. In step (E), which in general is optional but is preferred if there is any appreciable amount of reducing agent left after step D, residual hydride is removed. In step (F) the product, a cross- bridged macrocycle suitable for forming transition metal complexes which are useful bleach catalysts in detergents, is isolated. In step (G) optionally including one or more purification steps on the final product, transition metal complex of the cross- bridged macrocycle is formed. (A) - (G) occur in the indicated sequence.
SUMMARY OF THE INVENTION
In one aspect, the present invention relates to a method for preparing a cross- bridged macropolycycle, preferably a cross-bridged tetraazamacrocycle, comprising a series of steps, preferably three steps in sequence, of derivatizing cyclam or a particular acyclic tetraamine, wherein said series of steps is carried out using in common in each of said steps, substantially one solvent system. Preferably, said solvent system is an alcoholic solvent system; more preferably the solvent system comprises from about 60% to 100% of a C1-C4 alcohol, such as methanol, ethanol, n-propanol, 2-propanol, n-butanol, t-butanol, or mixtures thereof; ethanol and 2- propanol are preferred. More generally, and in preferred embodiments, mixtures of lower alcohol and, for example, from about 0.1% to about 70% water, more typically from about 1% to about 40% water, can also be useful and economic. In a highly preferred embodiment, said solvent system is substantially ethanol or mixtures thereof with water. The solvent system is preferably completely free from acetonitrile. Accordingly, the invention secures a "one-pot" method for making the cross-bridged macrocycle. "One pot" methods in general are highly advantageous - they permit reduced investment in manufacturing steps and equipment. Such an advantage is secured by the present process, which is simple, economic, and improved in terms of environmental acceptability.
The invention further relates to a method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of quatemizing an intermediate using a quatemizing agent, wherein said step is carried out using a minimized amount of said quatemizing agent.
The invention further relates to a method for preparing a cross-bridged macropolycycle comprising an alternate first step of forming a bisaminal by (i) reacting a suitable acyclic tetraamine with glyoxal to form a tricyclic macropolycycle and (ii) converting the tricyclic compound to the bisaminal by reacting it with a dihaloalkane, preferably and more generally a compound selected from the group consisting of α,τu-dichloroalkanes, α,tπ-dibromooalkanes, α,τσ- diiodoalkanes, α,τσ- ditosylalkanes and mixtures thereof, more preferably α,τjj- dibromooalkanes or α,τu- ditosylalkanes.
Preferably, the method of the invention has a second step which is carried out using less than about fifteen-fold of said quatemizing agent; typically, levels of about five-fold to about 10-fold of said quatemizing agent can be practiced. "Reagents" herein are materials, such as the glyoxal of step A, the quatemizing agent of step B, or the reducing agent of step C, which are chemically reacted with a macrocycle. Ratios of reagents herein, unless otherwise noted, are expressed on a molar basis; thus the term "three-fold" with respect to an amount of reagent over an amount of macrocycle means that the amount of reagent is three times the number of moles of the macrocycle it is being used to functionalize. A suitable quatemizing agent is methyl iodide, but the present method contains the further improvement of providing alternative, more environmentally attractive quatemizing agents further illustrated hereinafter. In another aspect, the present invention encompasses a method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of reducing a diquatemized intermediate, wherein said step is carried out using a minimized amount of reducing agent. Preferably, said step is carried out using an amount of less than about fifteen- fold of said reducing agent. More typically, the reducing agent is from about 2.5 - fold to about 10-fold the amount of macrocycle, on a molar basis.
In general, any suitable reducing agent, both catalytic and non-catalytic, may be used. For example, a tube reactor containing materials for catalytic hydrogenation providing a locally high concentration of reducing species can be used. Alternately, a preferred group of reducing agents herein, especially for the one-pot process, are non-catalytic reducing agents. For example Zn/HCl is a well- known reducing agent having the advantage that it can be used in water, and can be used herein. Preferred non-catalytic reducing agents are hydride compounds; more preferred are hydride compounds which can be used in wet (water-containing) systems. Preferred hydride compounds are borohydride and borane. Suitable borohydride compounds are selected from sodium borohydride and potassium borohydride. Less preferably, lithium borohydride can be used. When using borohydrides in methanol or ethanol herein, pH may be adjusted using small amounts of alkali to limit wasteful decomposition and release of hydrogen from the hydride. 2-propanol and t-butanol have known advantages of producing less wasteful hydrogen evolution than, say, methanol or ethanol.
The invention also encompasses a method in which sodium ion is substantially absent. The terms "substantially absent" or "substantially free" in connection with a material herein mean that the material is not deliberately added, though adventitious amounts are permissible. Surprisingly, sodium ion, though usable, has some adverse effect on the method, so sodium ion, other than adventitious amounts, are excluded in certain preferred embodiments.
Although the invention overall is not so limited, in a further aspect, the present invention relates to a method having each of the foregoing steps, in sequence. As noted, the steps can be carried out in "one pot" to secure the maximum advantages. Of course, the practitioner may choose not to secure the maximum benefits, for example if the different steps are carried out at multiple manufacturing locations, or for other reasons, such as a desire to use a specialized hydrogenation reactor in the third step. In this instance, practitioners may still avail themselves of the improvements in any one or two of the individual steps in any one manufacturing location or facility. In preferred embodiments, the invention further relates to the method described hereinabove which is carried out in the absence of any step of vacuum distilling an intermediate; and to a method which is carried out at low temperatures, especially wherein said quatemization and reduction steps are carried out at the low temperatures of from about ambient temperature to about 50°C, more preferably lower than about 50°C.
In preferred embodiments, all steps are carried out at concentrations of the reactants of about 7% or higher, by weight in total of the sum of reactants plus solvent; preferably, the concentrations of the reactants exceeds about 15% in total of the sum of reactants plus solvent. This permits the use of smaller and less costly manufacturing plant and the use of lower, safer amounts of flammable materials.
As will already be apparent, the invention secures numerous advantages in relation to the manufacture of cross-bridged macrocycles, as non-limitingly illustrated by cross-bridged cyclam derivatives. Indeed the advantages of the present method make a substantial difference to the possibility of commercially producing cross-bridged macrocycles for the useful purposes outlined in the background.
Finally, the present invention relates to a method for producing a complex of Mn with a cross-bridged macrocyclic ligand. Said method comprises preparing said complex, preferably under strictly oxygen and hydroxyl-free (ideally completely anhydrous) conditions by reaction of MnC-2 with a cross-bridged macropolycycle.
All ratios, proportions and percentages are by weight unless otherwise specifically indicated. An exception is yields. Yields are given as percentages obtained of the amounts expected for complete chemical reaction according to the equations given. Percentage yields can, of course, be computed on either a weight or a mole basis, given the designated reactions.
DETAILED DESCRIPTION OF THE INVENTION
In a preferred embodiment, the present invention involves a process or method having three essential steps, (A), (B) and (C) as shown in Figure 1, optionally followed by additional steps. In one such embodiment, Step (A) is non-limitingly illustrated as follows:
Figure imgf000008_0001
MF=C10H24N4 MF=C2H20240 % / r jO C12H22N4
MW=200 32 MW= 58 03 222 33
Moles =9 98 Moles = 9 98 222 184446
Mass = 2,000 gm Mass =1 ,448 5 mis (580 gm ) C 64 8% H 10 0% N 25 2% Source Aldnch The above step, the yield of which is from about 85% to 100%, typically near quantitative (100%), can be carried out using ethanol as a solvent and a concentration of reactants of 7%. The reagent, glyoxal, can be used pure or undiluted, or as a solution, for example and aqueous solution. More generally, in this step, the concentration of reactants by weight in the sum of all solvents including water, if present, is in the range from about 7% to about 20%, or higher. Thus, cyclam is slurried at 7% in ethanol. The slurry is stirred using any convenient stirring means, such as a mechanically driven paddle stirrer. The above depicted co- reactant, glyoxal, is dripped in, preferably keeping the temperature below about 35 ° C. More generally, the temperature can be in the range from about 10 °C to about 40 °C. After the addition reaction is over, typically within one hour, more generally in from about 10 min. to about 3 hours, it is found to be quantitative by any suitable means, for example C-13 NMR. Step (A) and all other steps herein can in general be conducted at atmospheric pressure, or overpressures if desired. The term "overpressures" herein means pressures greater than atmospheric. Although preferred embodiments of the invention include those conducted at atmospheric pressure, any step or steps can be conducted at overpressures, for example to contain volatile solvents or reagents above their normal boiling-points. The cis-tetracycle (product of step (A)) is not isolated; rather it is kept in the reaction solvent and the process proceeds to step (B).
In another preferred embodiment, the cis-tetracycle is prepared using the following scheme:
Figure imgf000009_0001
This alternate procedure is referred to as alternate Step (A), comprising step A (i) and step A(ii) as shown. In more detail, a suitable tetramine, N,N'-bis-(2- aminoethyl)-l,3-propanediamine, is reacted with glyoxal, typically about 1-10 molar equivalents, preferably from about 0.8 to about 1.5 molar equivalents, very suitably 1 molar equivalent, in a solvent, ethanol being preferred, at temperatures in the range from about 0 to 100°C, more preferably 0 to 25°C, for a period of from about 1 min. to about 7 days, preferably from about 15 min. to about 2 hours. The intermediate product, a tricycle of the shown structure, can either be isolated by distillation or can be further reacted to form the cis-tetracycle without changing reactor. The conversion of the tricycle to the cis-tetracycle can suitably be conducted using a 1,3- dihalopropane, typically 1,3-dibromopropane, or the ditosylate of 1,3-propanediol can alternatively be used. Suitable solvents are ethanol (ideal for one-pot purposes) or acetonitrile. A base is used to prevent the tricyclic amine reactant from protonating as the reaction continues. Suitable bases can vary widely and can include potassium carbonate or organic bases which are resistant to alkylation, such as di- isopropylethylamine (Kδenig's base). The amount of the base is typically from 1-10 equivalents, preferably from about 2 equivalents to about 6 equivalents. The reaction temperature is in the range from about 0 to 100°C, more preferably 0 to 30°C, for a period of from about 15 min. to about 7 days, preferably from about 30 min. to about 2 hours. Depending on the base used, workup can vary. With potassium carbonate, for example, the reaction mixture is filtered to remove solid base and the filtrate is evaporated to yield the cis-tetracycle as a solid. With an organic base, the solvent is evaporated and the evaporate is distilled. Step (B) is non-limitingly illustrated as follows:
CN NxN N3 + H'c-'
Figure imgf000010_0001
MF=C12H22N4 MF=CH3I C14H28I2N4
MW=222 33 MW= 141 93 506 21
Moles = 59 88 506 040351
Figure imgf000010_0002
gm Mass = 8500 gm C 33 2% H 5 6% I 50 1 % N 11 1 %
Source Aldπch
After making the cis tetracycle (product of any variation of step(A) ), this material is quatemized, as non-limitingly illustrated using alkyl halide (CH3I) in the reaction scheme. Such a step has a yield of about 80%), or higher. Yields of 80% can typically be achieved. More generally, in this step, the concentration of reactants by weight in the sum of all solvents including water, if present, is in the range from about 7% to about 20%, or higher. In a preferred embodiment, from about 2.01 to about 14 equivalents, preferably from about 2.5 to about 8 equivalents, for example 7 equivalents of methyl iodide are added to the reaction solution and the reaction is stirred using any convenient means, such as a mechanically driven stirrer (sparkless motor). More generally, any one or more alkyl halides can be used, for example a mixture of methyl iodide and 1-iodopropane. As will be seen from the working examples hereinafter, by introducing a second alkyl halide in addition to methyl iodide, step (B) is thereby modified to allow access to additional macrocyclic compounds as alternate products of the present process. The temperature is maintained in the general range from about 10 °C to about 38 °C, more preferably from about 15 °C to about 30 °C. At the low end of these reaction temperatures, there is a tendency for more monoquatemized intermediate (not shown in the reaction sequence) to precipitate. At the high end of these reaction temperatures, there is more tendency to form undesired byproducts, such as a triquatemized derivative (also not shown in the reaction sequence). Desirably, in view of byproduct formation tendencies, mono-quat intermediate is precipitated; but in order to maximize reaction rate, measures are taken to keep the particle size small and the surface area of intermediate mono-quat as high as possible. Vigorous stirring, small adjustments of the solvent system, or compatible additives, for example inert water- soluble nonsodium salts, can help. Illustrative of reaction time in step (B) is a period of from about 0.5 hours to 72 hours. Typical reaction times when not taking any special measures to accelerate reaction are from about 24 hours to about 72 hours, for example about 48 hours. The monoquat intermediate referred to supra usually begins to separate from solution about 1 hour after addition of methyl iodide. The reaction can desirably be monitored, for example by C-13 NMR. When reaction to form diquat is complete the ethanol can, if desired, be siphoned off (this is convenient, especially for the one-pot variation of the present process). Solvents are desirably recycled in this and all other steps where recycle is possible. Recycle can be by any convenient means, for example by means of conventional distillation apparatus. Solid product of step (B) can be washed with ethanol, typically several times, to remove excess methyl iodide. Step (B) can be conducted at atmospheric pressure; however, any suitable overpressure may be quite desirable when the quatemizing agent is low-boiling.
Other alkyl halides, such as chloromethane, or, more generally, other quatemizing agents such as dimethyl sulfate or methyltosylate, can be substituted in the above procedure. As noted, faster reaction times occur when the mono-quat is solubilized, but faster reaction times, for example using dimethyl sulfate / water / ethanol, may increase tendency to form an undesired tri-quat.
As noted, the desired product of this step, the di-quat compound shown in the illustration, is derived from an initially-formed and practically insoluble mono quat. Note that in relative terms, the di-quat compound is even more insoluble than the mono-quat. In order to accelerate the reaction, it might have been thought desirable to solublize the mono-quat; however, excessive solubilization of mono-quat intermediate, which, in turn, may lead to undesirable solubilization of diquat, is avoided in preferred embodiments of the present process, thereby limiting formation of undesired, tri quat byproduct.
Step fC is non-limitin giy illustrated as follows:
Figure imgf000012_0001
MF=C14H28I2N4 MF=NaBH44H30N4
MW=506.21 MW= 37.83 254.41 Moles =9.98 Moles = 120 254.247047 Mass = 5050 gm. Mass = 4,530 gm C 66.1 % H 11.9% N 22.0% Source :Aldrich
Step (C) is a reduction step, having typical yield of 80% or higher. The solids from the diquat reaction of step (B) are dissolved in water and ethanol is added to make a 80%) ethanol solution; the final concentration of the diquat is 20 % by weight in the total of solvents (for example 81 :19 ethanohwater by weight). More generally, C1-C4 lower alcohol may be used in all of steps (A), (B) and (C) and in step (C) a preferred solvent system comprises from about 50 % to about 95% lower alcohol and the balance water. An excess, preferably from about 3 to about 10, for example, 6, equivalents of sodium borohydride are added slowly, with stirring using any convenient means. For convenience, the borohydride may, for example, by slurried in a portion of solvent and added as the slurry, if it is desired to avoid solids-handling and obtain excellent control of the addition. On addition of the borohydride, the reaction becomes very exothermic. Temperature is maintained in the range from about 0 °C to about 80 °C, more preferably from about 20 °C to about 50 °, using cooling means such as an ice bath if needed. Once all borohydride is added, the reaction mixture is stirred, generally from about 1.5-72 hours, typically up to ethanol reflux. Longer reaction times at relatively lower temperatures are safest in this step (C) and safety may be further enhanced by passage of an inert gas, such as nitrogen, to flush out hydrogen, especially from the reactor headspace. Suitable reducing agents herein include the borohydrides, but preferably, nonsodium salt forms. Reaction is optionally monitored by ion spray mass spec.
This constitutes the end of the basic process: it will be seen that all the above has been accomplished using ethanol or equivalent lower alkanol (preferably with some water) as the solvent. The crude product is useful as an intermediate for further processing as illustrated herein. Steps (D)-(G)
As can be seen from Figure 1 and further illustrated in Figure 2, any of a range of alternative steps or combination of steps may follow step (C). For example, once the step (C) reaction is finished, a step identified as (E) in Fig. 1. can be used. In such a step, the pH is adjusted to between 1 and 2 with 37% HC1 (slow addition of acid is required, reaction is very exothermic) and the reaction solution is concentrated at reduced pressure to a thick slurry. The thick slurry is then made basic (pH>14), for example with 8M KOH. If desired, product can be extracted with toluene and subjected to further purification, such as by distillation. Preferred embodiments of the instant invention, however, include those not having vacuum distillation as a requirement.
An alternative procedure for workup, (D) in Figure 1, simply involves evaporating to dryness the crude product of step (C); the organic product is then separated from residual salts by extraction with ethanol. Another alternative workup, (F), is illustrated by a direct distillation of the desired product from the crude reaction mixture. The product can then be used for conversion to useful transition-metal complexes, especially the dichloro-Mn(II) complex, which are effective bleach catalysts, preferably by the present invention process by reaction with MnCl2-
In more detail, with reference to Figure 2, a preferred workup sequence comprises the steps of (D) (i) reducing agent removal, for example by simple filtration, (D) (ii) solvent removal, for example by evaporation, (E) residual hydride removal, for example by using acid-treatment followed by base treatment as defined supra, and (F) separation of the desired cross-bridged macrocycle, for example by distillation. The product of step (F) is used in subsequent step (G) to form a transition-metal complex, for example a complex of manganese.
A preferred product of the present process (product of step (C)), is 5,12- dimethyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane. This product is obtained when cyclam is used as the parent macrocycle. However, the invention methods should not be taken as limited to this particular material, as it is equally amenable to the preparation of any one of a wide range of cross-bridged macrocycles. For example, any one or more substituent moieties such as alkyl or alkaryl moieties, may be present, covalently attached to the parent macrocycle used in step (A). Moreover, other macrocycles can be made by the process through the variation of adding methyl halide along with another alkyl halide in step (B). Thus, for example, 5-n- butyl-12-methyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane can be prepared by the present process by use of a mixture of 1-iodobutane and methyl iodide, very preferably by consecutive reaction first of an equivalent of iodobutane then an equivalent of methyl iodide, in step (B). Similarly, the present process can be used to prepare the cross-bridged macrocycle 5-benzyl-12-methyl-l,5,8,12-tetraaza- bicyclo[6.6.2]hexadecane, simply by use of the variation of adding methyl iodide and benzyl bromide, instead of only methyl iodide, in step (B). All of these cross- bridged macrocycles can thus be prepared using the desirable features of the invention, for example their independence from use of dimethylformamide or acetonitrile and their improved yields, especially in step (A), all to great economic advantage.
In a preferred embodiment of the present invention, the macrocyclic ligand is reacted directly with manganese as an inorganic salt free of organic ligands such as pyridine, to form useful transition-metal complexes. The source of manganese chloride can include analytical and technical grades, and can be fully anhydrous or only partly anhydrous. Manganese chloride is commercially available from Chemetals Corp., Spectrum Bulk Chemicals Corp., American International Chemical Inc., Barker Industries Inc., and Mineral Research and Development Corp. As noted in Kirk-Othmer's Encyclopedia, manganese chloride can be prepared from the carbonate or oxide by dissolving it in hydrochloric acid. Heavy-metal contamination can be removed by precipitation through the addition of manganese carbonate which increases the pH. Following filtration, the solution can be concentrated and upon cooling, crystals of MnCl2-4H2O are collected. If an anhydrous product is desired, dehydration in a rotary dryer to a final temperature of 220°C is required. Anhydrous manganese chloride can also be made by reaction of manganese metal, carbonate or oxide, and dry hydrochloric acid. Manganese chloride is manufactured by Chemetals Corp., using a process in which manganese(II) oxide is leached with hydrochloric acid. Manganese carbonate is added after completion of the initial reaction to precipitate the heavy-metal impurities. Following filtration of the impurities, the solution is concentrated and cooled and the manganese chloride is isolated. Gradual heating in a rotary dryer above 200°C gives anhydrous manganese chloride. For top quality MnCl2.xH2θ grades, the starting-material is manganese metal or high purity MnO. To make anhydrous MnCl2 directly, manganese metal or ferromanganese is chlorinated at 700°C to 1000°C. Any iron trichloride initially present in the product is removed by sublimation. For more detail on manganese chloride, see Kirk Othmer's Encyclopedia of Chemical Technology, 4th Ed., Wiley, 1991, "Manganese Compounds", pp 991 and following. It is an advantage of the present invention to be able to proceed all the way from step (A) to step (G) (see Figure 1 ) without having to make an intermediate complex of manganese with an organic ligand. Moreover, although high-purity manganese chloride grades, especially those which are totally anhydrous, work very well in the instant invention, it is a further advantage to be able to use grades such as the 98%+ grade and the 99% grade which are not totally anhydrous and are available at substantially lower cost. On the other hand, for the most exacting purity, it can be desirable and is equally encompassed herein to use a manganese chloride which has been made by the anhydrous route from the pure metal.
The macropolycyclic ligands herein (product of step (C)) can be reacted with manganese chloride in any convenient manner. See Examples 10 and 11 , in each, see (b), Method (II). Any variation of such non-limiting illustrations of the process for step (G) of the instant invention are encompassed herein; for example, argon or nitrogen and degassing procedures while they can be useful for best results can be dispensed with, especially in larger-scale commercial operation; likewise rotary evaporation and other laboratory-scale procedures can readily be scaled up to commercial-scale equipment. Any convenient organic solvent can be used, for example acetonitrile, though other solvents are also possible. Typically the step (G) conversion of macrocyclic ligand to transition-metal complex is conducted at temperatures from about ambient to about 100°C, preferably from about 40°C to about 80°C; and no water is deliberately added to the solvent system. Pressures are typically atmospheric, though higher pressures may be used if desired, for example to help contain volatile solvents.
Figure imgf000015_0001
The present invention is further non-limitingly illustrated by the following examples.
EXAMPLE 1
The method of the invention illustrated by steps (A) + (B) + (C) as described in detail hereinabove is carried out using the following parameters:
Step A Reagents: Parent macrocycle, MW 506.21, 10 moles
Step B reagents: Product of step A and Methyl Iodide
Step C reagents: Product of Step B and Sodium Borohydride.
All steps are conducted in a single reaction vessel equipped with a mechanical stirrer and means for gas inlet and outlet. Purging of hydrogen is accomplished using nitrogren or argon.
Figure imgf000016_0001
* Using known densities, these volume ratios, provided for convenient handling of materials, can readily be converted to weight ratios in accordance with preferred weight ratios cited elsewhere herein.
EXAMPLE 2 The method of Example 1 is repeated, except that an equal number of moles of dimethylsulfate replaces the methyl iodide.
EXAMPLE 3 The method of Example 1 is repeated, except that potassium borohydride replaces sodium borohydride in equimolar amount.
EXAMPLE 4 The method of Example 1 is repeated, except that the solvent system is ethanol-only in steps A and B.
EXAMPLE 5 The method of Example 1 is repeated, except that the solvent system is substantially water.
EXAMPLE 6 The method of Example 1 is repeated, except that steps A and B are carried out in the original reaction vessel while step C is conducted in a second reaction vessel. The first reaction vessel is then freed from the requirement to handle hydrogen evolution.
EXAMPLE 7 The method of Example 1 is repeated, except that the reagent ratio to macrocycle is 1.1 -fold, 3-fold and 3-fold in steps (A), (B) and (C) respectively. (In the terms given in the Table of Example 1, column 5 numbers are 1.1 :1, 3:1 and 3:1). In another variation, a mixture of methyl iodide and 1-iodobutane replaces the methyl iodide of Example 1 , demonstrating that the present process can be used to prepare different kinds of cross-bridged macrocycles.
EXAMPLE 8 Purification of the product of Example 1. (Conventional) . Aqueous phase crude product from Example 1 is extracted with 5 portions of toluene. The extracts are combined and evaporated. The product is vacuum distilled at 100 C, 0.1 mm
Hg.
EXAMPLE 9 This example further illustrates the conversion of product of Example 1, after purification, to a useful bleach catalyst by the present invention process.
Figure imgf000017_0001
MF-C14H30N4 MF=MnCI2 C14H30CI2 n N4
380 26
MW=254 41 MW= 125 84
Moles = 5 99 Mo,es = 5 6 379 122798
C 44 2% H 8 0% Cl 18 6% Mn 14 4% N 14 7%
Mass = 1520 gm Mass = 704 7 gm
Source Aldπch
Reagents according to the present invention are in anhydrous form. Product of Example 1 after conventional purification (for example distillation) is slurried in a 10%) solution of acetonitrile and degassed with argon. Anhydrous MnCl2 (more economically, 98%> or 99% grade) is then added and the reaction refluxed under argon for 4 hours. Reaction can be monitored qualitatively by color; pale blue being positive indication reaction is proceeding normally - any ingress of air may cause darkening. The reaction mixture is then filtered hot through a glass micro fiber filter and, if desired, again through a 0.2 micron filter. Filtrate is then concentrated at reduced pressure to dryness and the solids suspended and washed 5X in 2 volumes of toluene and then filtered and dried.
EXAMPLE 10 - Synthesis of [Mn(Bcyclam)Cb]
This example also further illustrates the conversion of product of Example 1, after purification, to a useful bleach catalyst.
Figure imgf000018_0001
(a) Method I.
The "Bcyclam", (5,12-dimethyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane) , is the product of the process of the invention. Bcyclam (1.00 g., 3.93 mmol) is dissolved in dry CH3CN (35 mL, distilled from CaH2). The solution is then evacuated at 15 mm until the CH3CN begins to boil. The flask is then brought to atmospheric pressure with Ar. This degassing procedure is repeated 4 times. Mn(pyridine)2Cl2 (1.12 g., 3.93 mmol), synthesized according to the literature procedure of H. T. Witteveen et al., J. Inorg. Nucl. Chem.. (1974), 36, 1535, is added under Ar. The cloudy reaction solution slowly begins to darken. After stirring overnight at room temperature, the reaction solution becomes dark brown with suspended fine particulates. The reaction solution is filtered with a 0.2μ filter. The filtrate is a light tan color. This filtrate is evaporated to dryness using a rotoevaporator. After drying overnight at 0.05 mm at room temperature, 1.35 g. off- white solid product is collected, 90% yield. Elemental Analysis: %Mn, 14.45; %C, 44.22; %H, 7.95; theoretical for [Mn(Bcyclam)Cl ], MnCι4H3θN4Cl2, MW = 380.26. Found: %Mn, 14.98; %C, 44.48; %H, 7.86; Ion Spray Mass Spectroscopy shows one major peak at 354 mu corresponding to [Mn(Bcyclam)(formate)]+.
(b) Method II fPresent Invention Process!
Freshly distilled Bcyclam (25.00 g., 0.0984 mol), which is the product of the present process, is dissolved in dry CH3CN (900 mL, distilled from CaH2). The solution is then evacuated at 15 mm until the CH3CN begins to boil. The flask is then brought to atmospheric pressure with Ar. This degassing procedure is repeated 4 times. MnCl2 (11.25 g., 0.0894 mol) is added under Ar. The cloudy reaction solution immediately darkens. After stirring 4 hrs. under reflux, the reaction solution becomes dark brown with suspended fine particulates. The reaction solution is, if desired, filtered through a 0.2μ filter under dry conditions. The filtrate is a light tan color. This filtrate is evaporated to dryness using a rotoevaporator. The resulting tan solid is dried overnight at 0.05 mm at room temperature. The solid is suspended in toluene (100 mL) and heated to reflux. The toluene is decanted off and the procedure is repeated with another 100 mL of toluene. The balance of the toluene is removed using a rotoevaporator. After drying overnight at.05 mm at room temperature, 31.75 g. of a light blue solid product is collected, 93.5% yield. Elemental Analysis: %Mn, 14.45; %C, 44.22; %H, 7.95; %N, 14.73; %C1, 18.65; theoretical for [Mn(Bcyclam)Cl2], MnCi4H3QN4Cl2, MW = 380.26'. Found: %Mn, 14.69; %C, 44.69; %H, 7.99; %N, 14.78; %C1, 18.90 (Karl Fischer Water, 0.68%)). Ion Spray Mass Spectroscopy shows one major peak at 354 mu corresponding to [Mn(Bcyclam)(formate)]+.
Figure imgf000019_0001
5-n-butyl-12-methyl-1.5.8.12-tetraaza-bicyclo[6.6.2]hexadecane
Figure imgf000019_0002
(a) C -Bcyclam Synthesis
Figure imgf000019_0003
The following synthesis method is conventional and is included for comparative purposes; however the product, (III) (see hereinafter) is another macrocycle which can be manufactured by the hereinabove-described process of the present invention, simply by addition of an additional alkyl halide, 1 -iodobutane, to step (B) of the instant process. Tetracyclic adduct (I) can be made using step (A) of the instant process, or, for comparison, can be prepared by the literature method of H. Yamamoto and K. Maruoka, J. Amer. Chem. Soc. (1981) ,103, 4194. I (3.00 g., 13.5 mmol) is dissolved in dry CH3CN (50 mL, distilled from CaH2). 1 -Iodobutane (24.84 g., 135 mmol) is added to the stirred solution under Ar. The solution is stirred at room temperature for 5 days. 4-Iodobutane (12.42 g., 67.5 mmol) is added and the solution is stirred an additional 5 days at RT. Under these conditions, I is fully mono-alkylated with 1 -iodobutane as shown by 13C_NMR.. Methyl iodide (26.5 g, 187 mmol) is added and the solution is stirred at room temperature for an additional 5 days. The reaction is filtered using Whatman #4 paper and vacuum filtration. A white solid, II, is collected (6.05 g., 82%).
13C NMR (CDCI3) 16.3, 21.3, 21.6, 22.5, 25.8, 49.2, 49.4, 50.1, 51.4, 52.6, 53.9, 54.1, 62.3, 63.5, 67.9, 79.1, 79.2 ppm. Electro spray Mass Spec. (MH+/2, 147). II (6.00 g., 11.0 mmol) is dissolved in 95% ethanol (500 mL). Sodium borohydride (11.0 g., 290 mmol) is added and the reaction turns milky white. The reaction is stirred under Ar for three days. Hydrochloric acid (100 mL, concentrated) is slowly dripped into the reaction mixture over 1 hour. The reaction mixture is evaporated to dryness using a rotoevaporator. The white residue is dissolved in sodium hydroxide (500 mL, OON). This solution is extracted with toluene (2 x 150 mL). The toluene layers are combined and dried with sodium sulfate. After removal of the sodium sulfate using filtration, the toluene is evaporated to dryness using a rotoevaporator. The resulting oil is dried at room temperature under high vacuum (0.05 mm) ovemight. A colorless oil results 2.95 g., 90%. This oil (2.10 g.) is distilled using a short path distillation apparatus (still head temperature 115 C at 0.05 mm). Yield: 2.00 g. 13C NMR (CDC13) 14.0, 20.6, 27.2, 27.7, 30.5, 32.5, 51.2, 51.4, 54.1, 54.7, 55.1, 55.8, 56.1, 56.5, 57.9, 58.0, 59.9 ppm. Mass Spec. (MH+, 297).
(b) [Mn(C ]-Bcyclam Ch] Synthesis (According to the present invention) C4-Bcyclam (2.00 g., 6.76 mmol) is slurried in dry CH3CN (75 mL, distilled from CaH2). The solution is then evacuated at 15 mm until the CH3CN begins to boil. The flask is then brought to atmospheric pressure with Ar. This degassing procedure is repeated 4 times. MnCl2 (0.81 g., 6.43 mmol) is added under Ar. The tan, cloudy reaction solution immediately darkens. After stirring 4 hrs. under reflux, the reaction solution becomes dark brown with suspended fine particulates. The reaction solution is filtered through a 0.2μ membrane filter under dry conditions. The filtrate is a light tan color. This filtrate is evaporated to dryness using a rotoevaporator. The resulting white solid is suspended in toluene (50 mL) and heated to reflux. The toluene is decanted off and the procedure is repeated with another 100 mL of toluene. The balance of the toluene is removed using a rotoevaporator. After drying ovemight at 0.05 mm, RT, 2.4 g. a light blue solid (III) results, 88% yield. Ion Spray Mass Spectroscopy shows one major peak at 396 mu corresponding to [Mn(C4-Bcyclam)(formate)]+.
EXAMPLE 12. Synthesis of [MnfBz-BcvclarrACb] where Bz-Bcyclam = 5-benzyl-12-methyl-1.5.8.12-tetraaza-bicyclo[6.6.2]hexadecane
Figure imgf000020_0001
(a) Bz-Bcyclam Synthesis
The macrocycle is synthesized similarly to the C4-Bcyclam synthesis described above, except that benzyl bromide is used in place of the 1 -iodobutane in step (B) of the instant process. 13C NMR (CDCI3) 27.6, 28.4, 43.0, 52.1, 52.2, 54.4, 55.6, 56.4, 56.5, 56.9, 57.3, 57.8, 60.2, 60.3, 126.7, 128.0, 129.1, 141.0 ppm. Mass Spec. (MH+, 331).
(h) [MnfBz-BcyclairnCh] Synthesis
This complex is made similarly to the [Mn(C4-Bcyclam)Cl2] synthesis described above except that Bz-Bcyclam is used in place of the C4-Bcyclam. Ion Spray Mass Spectroscopy shows one major peak at 430 mu corresponding to [Mn(Bz-Bcyclam)(formate)]+.
EXAMPLE 13 . Synthesis of [MnfCg-Bcvclarr Cb] where Cg-Bcvclam = 5-n-octyl-12-methyl-1.5.8.12-tetraaza-bicyclo[6.6.2]hexadecane
Figure imgf000021_0001
(a) Cg-Bcyclam Synthesis:
This ligand is synthesized similarly to the C4-Bcyclam synthesis described above except that 1-iodooctane is used in place of the 1 -iodobutane. Mass Spec. (MH+, 353).
b) [MnfCg-BcyclanilCb] Synthesis
This complex is made similarly to the [Mn(C4-Bcyclam)Cl2] synthesis described above except that Cg-Bcyclam is used in place of the C4-Bcyclam.
Ion Spray Mass Spectroscopy shows one major peak at 452 mu corresponding to
[Mn(B8-Bcyclam)(formate)]+.
EXAMPLE 14. Synthesis of [Mnf^-BcyclanflCh] where H -Bcvclam = 1.5.8.12-tetraaza-bicyclo[6.6.2]hexadecane
Figure imgf000021_0002
The H2-Bcyclam is synthesized similarly to the C4-Bcyclam synthesis described above except that benzyl bromide is used in place of the 1 -iodobutane and the methyl iodide. The benzyl groups are removed by catalytic hydrogenation. Thus, the resulting 5,12-dibenzyl-l,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane and 10% Pd on charcoal is dissolved in 85% acetic acid. This solution is stirred 3 days at room temperature under 1 atm. of hydrogen gas. The solution is filtered though a 0.2 micron filter under vacuum. After evaporation of solvent using a rotary evaporator, the product is obtained as a colorless oil. Yield: 90+%>.
The Mn complex is made similarly to the [Mn(Bcyclam)Cl2] synthesis described hereinabove except that the that H2-Bcyclam is used in place of the Bcyclam. Elemental Analysis: %C, 40.92; %H, 7.44; %N, 15.91 ; theoretical for [Mn(H2- Bcyclam)Cl2], MnC12H26N4Cl2, MW = 352.2. Found: %C, 41.00; %H, 7.60; %N, 15.80. FAB+ Mass Spectroscopy shows one major peak at 317 mu corresponding to [Mn(H2-Bcyclam)Cl]+ and another minor peak at 352 mu corresponding to [Mn(H2-Bcyclam)Cl2]+.
EXAMPLE 15. Synthesis of [FefHo-BcyclamlCb] where H2-Bcvclam = 1.5.8.12-tetraaza-bicyclo[6.6.2]hexadecane
Figure imgf000022_0001
The Fe complex is made similarly to the [Mn(H2-Bcyclam)Cl2] synthesis described hereinabove except that the that anhydrous FeCl2 is used in place of the MnCl2. Elemental Analysis: %C, 40.82; %H, 7.42; %N, 15.87; theoretical for [Fe(H - Bcyclam)CbJ, FeC ^26^-2, MW = 353.1. Found: %C, 39.29; %H, 7.49; %N, 15.00. FAB+ Mass Spectroscopy shows one major peak at 318 mu corresponding to [Fe(H2~Bcyclam)Cl]+ and another minor peak at 353 mu corresponding to [Fe(H2-Bcyclam)Cl2]+.
EXAMPLE 16. Synthesis of:
Chloro^O-methyl-l^^O^^S-pentaaza-tetracyclo^ .^^.l ^'^.jpentacosa- 3,5,7(24),1 l,13,15(25)-hexaene manganese(II) hexafluorophosphate ,7(b); Trifluoromethanesulfono-20-methyl- 1 ,9,20,24,25-pentaaza tetracyclo[7.7.7.13'^.l ^'^.]pentacosa-3,5,7(24),l l,13,15(25)-hexaene manganese(II) trifluoromethanesulfonate, 7(c) and Thiocyanato-20-methyl-l,9,20,24,25-pentaaza- tetracyclo[7.7.7.13>7.1 ! l Λ 5.]pentacosa-3, 5,7(24), 11 ,13,15(25)-hexaene iron(II) thiocyanate, 7(d) fa) Synthesis of the ligand 20-methyl-1.9.20.24.25-pentaaza- tetracyclo[7.7.7.13 5 7.l π'15.]pentacosa-3,5,7(24),l l,13,15(25)-hexaene The ligand 7-methyl-3, 7, 11, 17-tetraazabicyclo[l 1.3.1 l7]heptadeca-l(17), 13, 15-triene is synthesized by the literature procedure of K. P. Balakrishnan et al., J. Chem. Soc, Dalton Trans., 1990, 2965.
7-methyl-3, 7, 11, 17-tetraazabicyclo[l 1.3.1 17]heptadeca-l(17), 13, 15- triene (1.49g, όmmol) and O,O'-bis(methanesulfonate)-2,6-pyridine dimethanol (1.77g, όmmol) are separately dissolved in acetonitrile (60ml). They are then added via a syringe pump (at a rate of 1.2ml/hour) to a suspension of anhydrous sodium carbonate (53g, 0.5mol) in acetonitrile (1380ml). The temperature of the reaction is maintained at 65 °C throughout the total reaction of 60 hours.
After cooling, the solvent is removed under reduced pressure and the residue is dissolved in sodium hydroxide solution (200ml, 4M). The product is then extracted with benzene (6 times 100ml) and the combined organic extracts are dried over anhydrous sodium sulfate. After filtration the solvent is removed under reduced pressure. The product is then dissolved in an acetonitrile/triethylamine mixture (95:5) and is passed through a column of neutral alumina (2.5 x 12cm). Removal of the solvent yields a white solid (0.93g, 44%>).
This product may be further purified by recrystallization from an ethanol/diethylether mixture combined with cooling at 0°C ovemight to yield a white crystalline solid. Anal. Calcd. for C21H29N5: C, 71.75; H, 8.32; N, 19.93. Found: C, 71.41; H, 8.00; N, 20.00. A mass spectrum displays the expected molecular ion peak [for C2iH3øN5]+ at m/z=352. The ! H NMR(400MHz, in CD3CN) spectrum exhibits peaks at δ=1.81 (m,4H); 2.19 (s, 3H); 2.56 (t, 4H); 3.52 (t,4H); 3.68 (AB, 4H), 4.13 (AB, 4H), 6.53 (d, 4H) and 7.07 (t, 2H). The 13C NMR(75.6MHz, in CD3CN) spectrum shows eight peaks at δ=24.05, 58.52, 60.95, 62.94, 121.5, 137.44 and 159.33 ppm.
All metal complexation reactions are performed in an inert atmosphere glovebox using distilled and degassed solvents. (b Complexation of the ligand L\ with bis(pyridine) manganese (II) chloride
Bis(pyridine)manganese (II) chloride is synthesized according to the literature procedure of H. T. Witteveen et al., J Inorg. Nucl. Chem., 1974, 3_6, 1535.
The ligand L\ (1.24g, 3.5mmol), triethylamine(0.35g, 3.5mmol) and sodium hexafluorophosphate (0.588g, 3.5mmol) are dissolved in pyridine (12ml). To this is added bis(pyridine)manganese (II) chloride and the reaction is stirred ovemight. The reaction is then filtered to remove a white solid. This solid is washed with acetonitrile until the washings are no longer colored and then the combined organic filtrates are evaporated under reduced pressure. The residue is dissolved in the minimum amount of acetonitrile and allowed to evaporate ovemight to produce bright red crystals. Yield: 0.8g (39%). Anal. Calcd. for C2iH3 iN5Mnι ClιPιF6: C, 43.00; H, 4.99 and N, 11.95. Found: C, 42.88; H, 4.80 and N 11.86. A mass spectrum displays the expected molecular ion peak [for C2iH3 ^N5Mnι Cl at m/z=441. The electronic spectrum of a dilute solution in water exhibits two absorption bands at 260 and 414nm (ε=1.47 x 103 and 773 M'^cm"! respectively). The IR spectrum (KBr) of the complex shows a band at 1600cm" 1 (pyridine), and strong bands at 840 and 558 cm"1 (PFg").
(c) Complexation of the ligand with manganese (II) trifluoromethanesulfonate Manganese (II) trifluoromethanesulfonate is prepared by the literature procedure of Bryan and Dabrowiak, Inorg. Chem., 1975, 14, 297.
Manganese (II) trifluoromethanesulfonate (0.883g, 2.5mmol) is dissolved in acetonitrile (5ml). This is added to a solution of the ligand Li (0.878g, 2.5mmol) and triethylamine (0.25g, 2.5mmol) in acetonitrile (5ml). This is then heated for two hours before filtering and then after cooling removal of the solvent under reduced pressure. The residue is dissolved in a minimum amount of acetonitrile and left to evaporate slowly to yield orange crystals. Yield 1.06g (60%). Anal. Calc. for Mn1C23H29N5S2F6O6: C, 39.20; H, 4.15 and N, 9.95. Found: C, 38.83; H, 4.35 and N, 10.10. The mass spectrum displays the expected peak for [MnιC22H29N5Sι.F3θ3]+ at m/z=555. The electronic spectrum of a dilute solution in water exhibits two absorption bands at 260 and 412nm (ε=9733 and 607 M"^cm"l respectively). The IR spectrum (KBr) of the complex shows a band at 1600 cm"l (pyridine) and 1260, 1160 and 1030cm-1(CF SO ).
(d Complexation of the ligand with iron (II) trifluoromethanesulfonate
Iron (II) trifluoromethanesulfonate is prepared in situ by the literature procedure Tait and Busch, Inorg. Synth.. 1978, XVIII, 7.
The ligand (0.833g, 2.5 mmol) and triethylamine (0.505g, 5mmol) are dissolved in acetonitrile (5ml). To this is added a solution of hexakis(acetonitrile) iron (II) trifluoromethanesulfonate (1.5g, 2.5mmol) in acetonitrile (5ml) to yield a dark red solution. Sodium thiocyanate (0.406g, 5mmol) is then added and the reaction stirred for a further hour. The solvent is then removed under reduced pressure and the resulting solid is recrystallized from methanol to produce red microcrystals. Yield: 0.65g (50%). Anal. Calc. for Fe1C23H29N7S2:C, 52.76; H, 5.59 and N, 18.74. Found: C 52.96; H, 5.53; N, 18.55. A mass spectrum displays the expected molecular ion peak [for FejC22H29 6Sι]+ at m/z=465. The H NMR (300MHz, CD3CN) δ=1.70(AB,2H), 2.0 (AB,2H), 2.24 (s,3H), 2.39 (m,2H), 2.70 (m,4H), 3.68 (m,4H), 3.95 (m,4H), 4.2 (AB,2H), 7.09 (d,2H), 7.19 (d,2H), 7.52 (t,lH), 7.61 (d,lH). The IR spectrum (KBr) of the spectmm shows peaks at 1608 cm" 1 (pyridine) and strong peaks at 2099 and 2037cm"l(SCN~).
The metal complexes can be used in detergents, for example by adding about 0.05%) of complex to a granular detergent containing 10% sodium perborate, to improve bleaching.
Purification of Catalyst
In general, the state of purity of the transition-metal oxidation catalyst of Example 9 can vary, provided that any impurities, such as byproducts of the synthesis, free ligand(s), unreacted transition-metal salt precursors, colloidal organic or inorganic particles, and the like, are not present in amounts which substantially decrease the utility of the transition-metal oxidation catalyst. It has been discovered to be desirable that the transition-metal oxidation catalyst should be purified. This can be done using any suitable means, such that the catalyst does not excessively consume available oxygen (AvO). Excessive AvO consumption is defined as including any instance of exponential decrease in AvO levels of bleaching, oxidizing or catalyzing solutions with time at 20-40°C. Preferred transition-metal oxidation catalysts, whether purified or not, when placed into dilute aqueous buffered alkaline solution at a pH of about 9 (carbonate/bicarbonate buffer) at temperatures of about 40°C, have a relatively steady decrease in AvO levels with time; in preferred cases, this rate of decrease is linear or approximately linear. In the preferred embodiments, there is a rate of AvO consumption at 40 deg C given by a slope of a graph of %AvO vs. time (in sec.) (hereinafter "AvO slope") of from about -0.0050 to about -0.0500, more preferably -0.0100 to about -0.0200. Thus, a preferred Mn(II) oxidation catalyst has an AvO slope of from about -0.0140 to about -0.0182; in contrast, a somewhat less preferred transition metal oxidation catalyst has an AvO slope of - 0.0286.
Preferred methods for determining AvO consumption in aqueous solutions of transition metal oxidation catalysts herein include the well-known iodometric method or its variants, such as methods commonly applied for hydrogen peroxide. See, for example, Organic Peroxides, Vol. 2., D. Swem (Ed.,), Wiley-Interscience, New York, 1971, for example the table at p. 585 and references therein including P.D. Bartlett and R. Altscul, J. Amer. Chem. Soc, 67, 812 (1945) and W.E. Cass, J. Amer. Chem. Soc, 68, 1976 (1946). Accelerators such as ammonium molybdate can be used. The general procedure used herein is to prepare an aqueous solution of catalyst and hydrogen peroxide in a mild alkaline buffer, for example carbonate/bicarbonate at pH 9, and to monitor the consumption of hydrogen peroxide by periodic removal of aliquots of the solution which are "stopped" from further loss of hydrogen peroxide by acidification using glacial acetic acid, preferably with chilling (ice). These aliquots can then be analyzed by reaction with potassium iodide, optionally but sometimes preferably using ammonium molybdate (especially low-impurity molybdate, see for example U.S. 4,596,701) to accelerate complete reaction, followed by back-titratation using sodium thiosulfate. Other variations of analytical procedure can be used, such as thermometric procedures, potential buffer methods (Ishibashi et al., Anal. Chim. Acta (1992), 261(1-2), 405- 10) or photometric procedures for determination of hydrogen peroxide (EP 485,000 A2, May 13, 1992). Variations of methods permitting fractional determinations, for example of peracetic acid and hydrogen peroxide, in presence or absence of the instant transition-metal oxidation catalysts are also useful; see, for example JP 92- 303215, Oct. 16, 1992.
In another embodiment of the present invention, there are encompassed laundry and cleaning compositions incorporating transition-metal oxidation catalysts which have been purified to the extent of having a differential AvO loss reduction , relative to the untreated catalyst, of at least about 10 %> (units here are dimensionless since they represent the ratio of the AvO slope of the treated transition-metal oxidation catalyst over the AvO slope for the untreated transition metal oxidation catalyst - effectively a ratio of AvO's). In other terms, the AvO slope is improved by purification so as to bring it into the above-identified preferred ranges.
In yet another embodiment of the instant invention, two processes have been identified which are particularly effective in improving the suitability of transition- metal oxidation catalysts, as synthesized, for incorporation into laundry and cleaning products or for other useful oxidation catalysis applications.
One such process is any process having a step of treating the transition-metal oxidation catalyst, as prepared, by extracting the transition-metal oxidation catalyst, in solid form, with an aromatic hydrocarbon solvent; suitable solvents are oxidation- stable under conditions of use and include benzene and toluene, preferably toluene. Surprisingly, toluene extraction can measurably improve the AvO slope (see disclosure hereinabove).
Another process which can be used to improve the AvO slope of the transition metal oxidation catalyst is to filter a solution thereof using any suitable filtration means for removing small or colloidal particles. Such means include the use of fine-pore filters; centrifugation; or coagulation of the colloidal solids.
In more detail, a full procedure for purifying a transition-metal oxidation catalyst herein can include: (a) dissolving the transition-metal oxidation catalyst, as prepared, in hot acetonitrile:
(b) filtering the resulting solution hot, e.g., at about 70°C, through glass microfibers (for example glass microfiber filter paper available from Whatman);
(c) if desired, filtering the solution of the first filtration through a 0.2 micron membrane, (for example, a 0.2 micron filter commercially available from Millipore), or centrifuging, whereby colloidal particles are removed;
(d) evaporating the solution of the second filtration to dryness;
(e) washing the solids of step (d) with toluene, for example five times using toluene in an amount which is double the volume of the oxidation catalyst solids;
(f) drying the product of step (e).
Another procedure which can be used, in any convenient combination with aromatic solvent washes and/or removal of fine particles is recrystallization. Recrystallization, for example of Mn(II) Bcyclam chloride transition-metal oxidation catalyst, can be done from hot acetonitrile. Recrystallization can have its disadvantages, for example it may on occasion be more costly.

Claims

What is claimed is:
1. A method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine, wherein said series of steps is carried out using in common in said steps one solvent system.
2. A method according to Claim 1 wherein said solvent system is an alcoholic solvent system, preferably 60% to 100% of a C1-C4 alcohol or mixtures thereof.
3. A method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of quatemizing an intermediate using a quatemizing agent, wherein said step is carried out using of less than fifteen-fold of said quatemizing agent.
4. A method according to Claim 3 wherein said step is carried out using from five-fold to ten-fold of said quate izing agent selected from methyl iodide, methyl tosylate, and dimethyl sulfate.
5. A method for preparing a cross-bridged macropolycycle comprising a series of steps of derivatizing cyclam or a particular acyclic tetraamine including a step of reducing a diquaternized intermediate, wherein said step is carried out using an amount of less than fifteen-fold of reducing agent.
6. A method according to Claim 5 wherein said reducing agent is a non-catalytic reducing agent, preferably a borohydride.
7. A method for preparing a cross-bridged macropolycycle, said method comprising derivatizing cyclam or a particular acyclic tetraamine by a series of steps including:
- quatemizing an intermediate using a quatemizing agent, wherein said step is carried out using of less than fifteen-fold of said quatemizing agent; and
- reducing a diquaternized intermediate, wherein said step is carried out using an amount of less than fifteen-fold of reducing agent; and wherein further said series of steps is carried out using in common in said steps one solvent system.
8. A method for producing a complex of Mn and a cross-bridged macropoly- cyclic ligand, said method comprising reacting with manganous chloride a cross- bridged macropolycycle.
9. A method for preparing a transition metal complex of a cross-bridged macropolycycle comprising a series of steps of
(A) forming a bisaminal from an acyclic amine;
(B) forming a diquat derivative of said bisaminal;
(C) reducing said diquat derivative;
(D) separating reducing agent and solvent from the product of step (C) in one or more operations;
(E) removing residual hydride from the product of (D);
(F) isolating a cross-bridged tetraazamacrocycle product of steps (A) - (E); and
(G) reacting the product of step (F) with a transition-metal, thereby forming a transition-metal complex useful as a catalyst in detergent compositions.
10. A method according to any of Claims 1-9 which is carried out at or below 50°C.
11. A method according to any of Claims 1-10 wherein all of said steps are carried out at concentrations of the reactants of 7% or higher in total of the sum of reactants plus solvent.
PCT/IB1998/000299 1997-03-07 1998-03-06 Improved methods of making cross-bridged macropolycycles Ceased WO1998039335A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69830574T DE69830574T2 (en) 1997-03-07 1998-03-06 IMPROVED METHOD FOR THE PRODUCTION OF NETWORKED BRANCHED MACROPOLYCYCLES
JP53831198A JP4376320B2 (en) 1997-03-07 1998-03-06 Improved process for producing cross-linked macropolycyclic molecules
CA002282477A CA2282477C (en) 1997-03-07 1998-03-06 Improved methods of making cross-bridged macropolycycles
AT98904331T ATE297928T1 (en) 1997-03-07 1998-03-06 IMPROVED METHODS FOR PRODUCING CROSS-LINKED BRIDGED MACROPOLYCYCLES
AU62261/98A AU6226198A (en) 1997-03-07 1998-03-06 Improved methods of making cross-bridged macropolycycles
EP98904331A EP0971927B1 (en) 1997-03-07 1998-03-06 Improved methods of making cross-bridged macropolycycles
BR9808657-0A BR9808657A (en) 1997-03-07 1998-03-06 Improved methods of producing cross-linked macropolicycles
US09/380,675 US6225464B1 (en) 1997-03-07 1998-03-06 Methods of making cross-bridged macropolycycles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3992097P 1997-03-07 1997-03-07
US60/039,920 1997-03-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/380,675 A-371-Of-International US6225464B1 (en) 1997-03-07 1998-03-06 Methods of making cross-bridged macropolycycles
US09/832,579 Continuation US6444808B2 (en) 1997-03-07 2001-04-11 Methods of making cross-bridged macropolycycles

Publications (1)

Publication Number Publication Date
WO1998039335A1 true WO1998039335A1 (en) 1998-09-11

Family

ID=21908062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/000299 Ceased WO1998039335A1 (en) 1997-03-07 1998-03-06 Improved methods of making cross-bridged macropolycycles

Country Status (11)

Country Link
US (2) US6225464B1 (en)
EP (1) EP0971927B1 (en)
JP (1) JP4376320B2 (en)
CN (3) CN1263759C (en)
AT (1) ATE297928T1 (en)
AU (1) AU6226198A (en)
BR (1) BR9808657A (en)
CA (2) CA2282477C (en)
DE (1) DE69830574T2 (en)
ES (1) ES2245020T3 (en)
WO (1) WO1998039335A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029413A1 (en) * 1998-11-13 2000-05-25 The Procter & Gamble Company Process for preparing cross-bridged tetraaza macrocycles
WO2000029537A1 (en) * 1998-11-13 2000-05-25 The Procter & Gamble Company Bleach compositions
WO2000032601A3 (en) * 1998-11-30 2000-10-05 Procter & Gamble Process for preparing cross-bridged tetraaza macrocycles
EP0940402A3 (en) * 1998-03-05 2002-07-10 Clariant GmbH Quaternary polycyclic polyammonium salts and process for their preparation
WO2002026267A3 (en) * 2000-09-25 2003-04-03 Procter & Gamble Manganes complexes for magnetic resonance imaging
US6627176B2 (en) * 2000-09-25 2003-09-30 Procter & Gamble Company Metal complexes for use in medical and therapeutic applications
US6667288B2 (en) 1998-11-13 2003-12-23 Procter & Gamble Company Bleach compositions
US8034800B2 (en) 2004-06-10 2011-10-11 University Of Hull Antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
DE102011010818A1 (en) 2011-02-10 2012-08-16 Clariant International Ltd. Use of transition metal complexes as bleaching catalysts in detergents and cleaners

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263759C (en) * 1997-03-07 2006-07-12 宝洁公司 Improving method for preparing cross-bridge macrocylic compound
US20050187126A1 (en) * 2002-08-27 2005-08-25 Busch Daryle H. Catalysts and methods for catalytic oxidation
AU732147B2 (en) 1997-03-07 2001-04-12 Procter & Gamble Company, The Bleach compositions
US20020173644A1 (en) * 1997-03-07 2002-11-21 Hiler George Douglas Methods of making cross-bridged macropolycycles
US20030017941A1 (en) 1997-03-07 2003-01-23 The Procter & Gamble Company Catalysts and methods for catalytic oxidation
ZA981883B (en) * 1997-03-07 1998-09-01 Univ Kansas Catalysts and methods for catalytic oxidation
US20080125344A1 (en) * 2006-11-28 2008-05-29 Daryle Hadley Busch Bleach compositions
US6653270B2 (en) 1999-03-02 2003-11-25 Procter & Gamble Company Stabilized bleach compositions
US7169744B2 (en) 2002-06-06 2007-01-30 Procter & Gamble Company Organic catalyst with enhanced solubility
US7557076B2 (en) 2002-06-06 2009-07-07 The Procter & Gamble Company Organic catalyst with enhanced enzyme compatibility
US20040048763A1 (en) * 2002-08-27 2004-03-11 The Procter & Gamble Co. Bleach compositions
US20050113246A1 (en) * 2003-11-06 2005-05-26 The Procter & Gamble Company Process of producing an organic catalyst
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
WO2005052146A2 (en) 2003-11-19 2005-06-09 Genencor International, Inc. Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same
EP2292743B1 (en) 2003-12-03 2013-08-21 Danisco US Inc. Perhydrolase
US8476052B2 (en) * 2003-12-03 2013-07-02 Danisco Us Inc. Enzyme for the production of long chain peracid
US7754460B2 (en) * 2003-12-03 2010-07-13 Danisco Us Inc. Enzyme for the production of long chain peracid
US20050159327A1 (en) * 2004-01-16 2005-07-21 The Procter & Gamble Company Organic catalyst system
US20070196502A1 (en) * 2004-02-13 2007-08-23 The Procter & Gamble Company Flowable particulates
US20050181969A1 (en) * 2004-02-13 2005-08-18 Mort Paul R.Iii Active containing delivery particle
US7125535B2 (en) * 2004-03-11 2006-10-24 Afton Chemical Corporation Method of preparing anhydrous manganese chloride
US7425527B2 (en) * 2004-06-04 2008-09-16 The Procter & Gamble Company Organic activator
US20050276831A1 (en) * 2004-06-10 2005-12-15 Dihora Jiten O Benefit agent containing delivery particle
US20050288200A1 (en) * 2004-06-24 2005-12-29 Willey Alan D Photo Bleach Compositions
US7686892B2 (en) 2004-11-19 2010-03-30 The Procter & Gamble Company Whiteness perception compositions
EP1661977A1 (en) * 2004-11-29 2006-05-31 The Procter & Gamble Company Detergent compositions
AR051659A1 (en) * 2005-06-17 2007-01-31 Procter & Gamble A COMPOSITION THAT INCLUDES AN ORGANIC CATALYST WITH IMPROVED ENZYMATIC COMPATIBILITY
PL1754781T3 (en) 2005-08-19 2013-09-30 Procter & Gamble A solid laundry detergent composition comprising anionic detersive surfactant and a calcium-augmented technology
US20070044824A1 (en) 2005-09-01 2007-03-01 Scott William Capeci Processing system and method of processing
EP1948775B1 (en) * 2005-09-27 2017-01-11 The Procter & Gamble Company Microcapsule and method of producing same
KR20080066921A (en) 2005-10-12 2008-07-17 제넨코 인터내셔날 인코포레이티드 Use and preparation of storage-stable neutral metalloproteases
ES2377571T3 (en) * 2005-10-24 2012-03-29 The Procter & Gamble Company Compositions and systems for the care of tissues comprising organosilicone microemulsions and methods employing them
US7678752B2 (en) * 2005-10-24 2010-03-16 The Procter & Gamble Company Fabric care composition comprising organosilicone microemulsion and anionic/nitrogen-containing surfactant system
US20070123440A1 (en) * 2005-11-28 2007-05-31 Loughnane Brian J Stable odorant systems
EP1954814A2 (en) * 2005-12-09 2008-08-13 Genencor International, Inc. Acyltransferase useful for decontamination
CA2635947A1 (en) * 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and photobleach containing compositions
RU2479627C2 (en) * 2006-01-23 2013-04-20 Дзе Проктер Энд Гэмбл Компани Compositions of detergents
US7674757B2 (en) * 2006-01-23 2010-03-09 Milliken & Company Laundry care compositions with thiazolium dye
EP2248882A1 (en) * 2006-01-23 2010-11-10 The Procter and Gamble Company Enzyme and fabric hueing agent containing compositions
US20070191247A1 (en) * 2006-01-23 2007-08-16 The Procter & Gamble Company Detergent compositions
WO2007099469A2 (en) * 2006-02-28 2007-09-07 The Procter & Gamble Company Benefit agent containing delivery particle
MX2008011092A (en) * 2006-03-02 2008-09-10 Genencor Int Surface active bleach and dynamic ph.
MX336769B (en) * 2006-04-20 2016-01-28 Procter & Gamble Flowable particulates.
US20080027575A1 (en) * 2006-04-21 2008-01-31 Jones Stevan D Modeling systems for health and beauty consumer goods
US7629158B2 (en) 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
US20080025960A1 (en) * 2006-07-06 2008-01-31 Manoj Kumar Detergents with stabilized enzyme systems
EP2046269B1 (en) 2006-08-01 2010-12-15 The Procter & Gamble Company Benefit agent containing delivery particle
ES2403879T3 (en) 2006-11-22 2013-05-22 Appleton Papers Inc. Administration particle containing a beneficial agent
US20080177089A1 (en) 2007-01-19 2008-07-24 Eugene Steven Sadlowski Novel whitening agents for cellulosic substrates
WO2008100411A1 (en) * 2007-02-09 2008-08-21 The Procter & Gamble Company Perfume systems
MX2009008789A (en) 2007-02-15 2009-08-24 Procter & Gamble Benefit agent delivery compositions.
US20080305977A1 (en) * 2007-06-05 2008-12-11 The Procter & Gamble Company Perfume systems
CA2687560C (en) 2007-06-11 2013-05-14 The Procter & Gamble Company Benefit agent containing delivery particle
US8021436B2 (en) 2007-09-27 2011-09-20 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a xyloglucan conjugate
US20090094006A1 (en) 2007-10-03 2009-04-09 William David Laidig Modeling systems for consumer goods
CA2704311C (en) 2007-11-01 2018-02-13 Danisco Us Inc. Production of thermolysin and variants thereof, and use in liquid detergents
EP2071017A1 (en) 2007-12-04 2009-06-17 The Procter and Gamble Company Detergent composition
PL2242830T5 (en) * 2008-01-04 2021-08-16 The Procter & Gamble Company Enzyme and fabric hueing agent containing compositions
BRPI0822230A2 (en) * 2008-01-04 2015-06-23 Procter & Gamble Laundry detergent composition comprising a glycosyl hydrolase and a release particle containing beneficial agent.
EP2085070A1 (en) * 2008-01-11 2009-08-05 Procter & Gamble International Operations SA. Cleaning and/or treatment compositions
EP2083065A1 (en) 2008-01-22 2009-07-29 The Procter and Gamble Company Colour-Care Composition
CN101945996A (en) * 2008-02-11 2011-01-12 丹尼斯科美国公司 Has an active enzyme of microbial lytic from Trichodermareesei
EP2240579B1 (en) 2008-02-14 2017-05-03 Danisco US Inc. Small enzyme-containing granules
US20090209447A1 (en) * 2008-02-15 2009-08-20 Michelle Meek Cleaning compositions
WO2009101593A2 (en) * 2008-02-15 2009-08-20 The Procter & Gamble Company Delivery particle
CA2715795A1 (en) * 2008-03-26 2009-10-01 The Procter & Gamble Company Delivery particle having a shell of water insoluble inorganic meterial
US7923426B2 (en) * 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
CA2726451A1 (en) 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
EP2135933B1 (en) * 2008-06-20 2013-04-03 The Procter and Gamble Company Laundry composition
PL2272941T3 (en) 2008-06-20 2014-01-31 Procter & Gamble Laundry composition
US8974547B2 (en) * 2008-07-30 2015-03-10 Appvion, Inc. Delivery particle
EP2163606A1 (en) * 2008-08-27 2010-03-17 The Procter and Gamble Company A detergent composition comprising gluco-oligosaccharide oxidase
EP2163608A1 (en) 2008-09-12 2010-03-17 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye and fatty acid soap
EP2166078B1 (en) * 2008-09-12 2018-11-21 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye
EP2166077A1 (en) * 2008-09-12 2010-03-24 The Procter and Gamble Company Particles comprising a hueing dye
MX2011004847A (en) * 2008-11-07 2011-05-30 Procter & Gamble Benefit agent containing delivery particle.
AR074105A1 (en) 2008-11-11 2010-12-22 Danisco Us Inc COMPOSITIONS AND METHODS THAT INCLUDE SUBTILISIN VARIANTS
MX2011004803A (en) 2008-11-11 2011-06-16 Danisco Inc Compositions and methods comprising a subtilisin variant.
CN102209778B (en) * 2008-11-11 2014-10-15 丹尼斯科美国公司 compositions and methods comprising serine protease variants
US8753861B2 (en) 2008-11-11 2014-06-17 Danisco Us Inc. Protease comprising one or more combinable mutations
BRPI0922770A2 (en) * 2008-12-01 2019-09-24 Procter & Gamble perfume systems
US8754028B2 (en) * 2008-12-16 2014-06-17 The Procter & Gamble Company Perfume systems
US20100190673A1 (en) * 2009-01-29 2010-07-29 Johan Smets Encapsulates
US20100190674A1 (en) * 2009-01-29 2010-07-29 Johan Smets Encapsulates
BRPI1015050A2 (en) 2009-04-02 2016-04-12 Procter & Gamble a composition comprising release particles, said particles, consumer product, method of treatment and / or cleaning and said location
US8875798B2 (en) * 2009-04-27 2014-11-04 National Oilwell Varco, L.P. Wellsite replacement system and method for using same
CN102428166A (en) * 2009-05-15 2012-04-25 宝洁公司 Fragrance system
US20100305019A1 (en) * 2009-06-01 2010-12-02 Lapinig Daniel Victoria Hand Fabric Laundering System
EP2449077A1 (en) 2009-06-30 2012-05-09 The Procter & Gamble Company Fabric care compositions, process of making, and method of use
WO2011002825A1 (en) 2009-06-30 2011-01-06 The Procter & Gamble Company Rinse added aminosilicone containing compositions and methods of using same
US20110005001A1 (en) 2009-07-09 2011-01-13 Eric San Jose Robles Detergent Composition
ES2684470T3 (en) 2009-07-10 2018-10-03 The Procter & Gamble Company Compositions containing beneficial agent release particles
MX2012000490A (en) * 2009-07-10 2012-01-27 Procter & Gamble Compositions containing benefit agent delivery particles.
WO2011016958A2 (en) 2009-07-27 2011-02-10 The Procter & Gamble Company Detergent composition
WO2011056904A1 (en) * 2009-11-06 2011-05-12 The Procter & Gamble Company High efficiency particle comprising benefit agent
MX2012006616A (en) 2009-12-09 2012-06-21 Procter & Gamble Fabric and home care products.
US8728790B2 (en) 2009-12-09 2014-05-20 Danisco Us Inc. Compositions and methods comprising protease variants
WO2011075556A1 (en) 2009-12-18 2011-06-23 The Procter & Gamble Company Composition comprising encapsulates, and process for making them
JP2013513720A (en) 2009-12-18 2013-04-22 ザ プロクター アンド ギャンブル カンパニー Fragrance and fragrance inclusion body
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
BR112012017056A2 (en) 2009-12-21 2016-11-22 Danisco Us Inc "Bacillus subtilis lipase-containing detergent compositions and methods for using them"
CN102712879A (en) 2009-12-21 2012-10-03 丹尼斯科美国公司 Detergent compositions containing thermobifida fusca lipase and methods of use thereof
WO2011090957A2 (en) 2010-01-21 2011-07-28 The Procter & Gamble Company Process of preparing a particle
WO2011100420A1 (en) 2010-02-12 2011-08-18 The Procter & Gamble Company Benefit compositions comprising crosslinked polyglycerol esters
US20110201534A1 (en) 2010-02-12 2011-08-18 Jennifer Beth Ponder Benefit compositions comprising polyglycerol esters
WO2011100411A1 (en) 2010-02-12 2011-08-18 The Procter & Gamble Company Benefit compositions comprising polyglycerol esters
WO2011100405A1 (en) 2010-02-12 2011-08-18 The Procter & Gamble Company Benefit compositions comprising crosslinked polyglycerol esters
WO2011109322A1 (en) 2010-03-04 2011-09-09 The Procter & Gamble Company Detergent composition
US20110245136A1 (en) 2010-04-06 2011-10-06 Johan Smets Encapsulates
JP2012526188A (en) 2010-04-06 2012-10-25 ザ プロクター アンド ギャンブル カンパニー capsule
WO2011130222A2 (en) 2010-04-15 2011-10-20 Danisco Us Inc. Compositions and methods comprising variant proteases
MX2012012242A (en) 2010-04-19 2012-11-23 Procter & Gamble Detergent composition.
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US20110269657A1 (en) 2010-04-28 2011-11-03 Jiten Odhavji Dihora Delivery particles
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
EP3095861B1 (en) 2010-05-06 2019-06-26 The Procter and Gamble Company Consumer products with protease variants
EP2571941A2 (en) 2010-05-18 2013-03-27 Milliken & Company Optical brighteners and compositions comprising the same
WO2011146604A2 (en) 2010-05-18 2011-11-24 Milliken & Company Optical brighteners and compositions comprising the same
US20110294715A1 (en) 2010-05-26 2011-12-01 Johan Smets Encapsulates
US8476216B2 (en) 2010-05-28 2013-07-02 Milliken & Company Colored speckles having delayed release properties
AR081423A1 (en) 2010-05-28 2012-08-29 Danisco Us Inc DETERGENT COMPOSITIONS WITH STREPTOMYCES GRISEUS LIPASE CONTENT AND METHODS TO USE THEM
JP5744192B2 (en) 2010-06-22 2015-07-01 ザ プロクター アンド ギャンブルカンパニー Perfume
EP3287511A1 (en) 2010-06-22 2018-02-28 The Procter & Gamble Company Perfume systems
MX339494B (en) 2010-06-30 2016-05-26 Procter & Gamble Rinse added aminosilicone containing compositions and methods of using same.
MX2013000792A (en) 2010-07-20 2013-02-27 Procter & Gamble Particles with a plurality of coatings.
AR083328A1 (en) 2010-07-20 2013-02-21 Procter & Gamble SUPPLY PARTICLE
EP2619299B1 (en) 2010-09-20 2018-02-28 Wacker Chemie AG Fabric care formulations and methods
EP2619272B1 (en) 2010-09-20 2017-12-06 The Procter and Gamble Company Non-fluoropolymer surface protection composition
CN103228734A (en) 2010-09-20 2013-07-31 宝洁公司 Non-fluoropolymer surface protection composition
WO2012057781A1 (en) 2010-10-29 2012-05-03 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a fungal serine protease
WO2011026154A2 (en) 2010-10-29 2011-03-03 The Procter & Gamble Company Cleaning and/or treatment compositions
US8715368B2 (en) 2010-11-12 2014-05-06 The Procter & Gamble Company Thiophene azo dyes and laundry care compositions containing the same
PL2468239T3 (en) 2010-12-21 2014-02-28 Procter & Gamble Int Operations Sa Encapsulates
CN103492062A (en) 2011-02-25 2014-01-01 美利肯公司 Capsules and compositions containing them
WO2012138690A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
WO2012142087A1 (en) 2011-04-12 2012-10-18 The Procter & Gamble Company Metal bleach catalysts
WO2012149333A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing bacillus sp. mannanase and methods of use thereof
EP2712363A1 (en) 2011-04-29 2014-04-02 Danisco US Inc. Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof
US8802388B2 (en) 2011-04-29 2014-08-12 Danisco Us Inc. Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof
CN103764823B (en) 2011-05-05 2018-05-11 丹尼斯科美国公司 Compositions and methods comprising serine protease variants
JP5933688B2 (en) 2011-05-05 2016-06-15 ザ プロクター アンド ギャンブル カンパニー Compositions and methods comprising serine protease variants
US20140371435A9 (en) 2011-06-03 2014-12-18 Eduardo Torres Laundry Care Compositions Containing Thiophene Azo Dyes
EP2537918A1 (en) 2011-06-20 2012-12-26 The Procter & Gamble Company Consumer products with lipase comprising coated particles
WO2012175401A2 (en) 2011-06-20 2012-12-27 Novozymes A/S Particulate composition
BR112013033049A2 (en) 2011-06-23 2017-01-31 Procter & Gamble perfume systems
MX2013015187A (en) 2011-06-27 2014-02-17 Procter & Gamble Stable polymer containing two phase systems.
CN103747771A (en) 2011-08-10 2014-04-23 宝洁公司 Encapsulation
AR087745A1 (en) 2011-08-31 2014-04-16 Danisco Us Inc COMPOSITIONS AND METHODS THAT INCLUDE A VARIANT OF LIPOLITIC ENZYME
BR112014005193A2 (en) 2011-09-13 2017-03-21 Procter & Gamble encapsulated
EP2581438A1 (en) 2011-10-12 2013-04-17 The Procter and Gamble Company Detergent composition
CN103174011A (en) * 2011-11-24 2013-06-26 东华大学 Application of tetranitrogen bicyclotetradecane metal complex to low-temperature scouring and bleaching auxiliary for textiles
US20150017700A1 (en) 2011-12-22 2015-01-15 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
ES2673844T3 (en) 2012-01-18 2018-06-26 The Procter & Gamble Company Perfume systems
MX353896B (en) 2012-02-03 2018-02-01 Procter & Gamble Compositions and methods for surface treatment with lipases.
EP2809779B1 (en) 2012-02-03 2017-09-13 Novozymes A/S Lipase variants and polynucleotides encoding same
CA2867714A1 (en) 2012-03-19 2013-09-26 The Procter & Gamble Company Laundry care compositions containing dyes
CA2867296C (en) 2012-03-26 2016-09-27 The Procter & Gamble Company Cleaning compositions comprising ph-switchable amine surfactants
CN107988181A (en) 2012-04-02 2018-05-04 诺维信公司 Lipase Variant and the polynucleotides for encoding it
WO2013171241A1 (en) 2012-05-16 2013-11-21 Novozymes A/S Compositions comprising lipase and methods of use thereof
EP2674475A1 (en) 2012-06-11 2013-12-18 The Procter & Gamble Company Detergent composition
WO2014009473A1 (en) 2012-07-12 2014-01-16 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
US9796952B2 (en) 2012-09-25 2017-10-24 The Procter & Gamble Company Laundry care compositions with thiazolium dye
EP2712915A1 (en) 2012-10-01 2014-04-02 The Procter and Gamble Company Methods of treating a surface and compositions for use therein
CA2885774C (en) 2012-10-04 2019-04-02 Ecolab Usa Inc. Pre-soak technology for laundry and other hard surface cleaning
HK1209785A1 (en) 2012-10-12 2016-04-08 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
CA2888342A1 (en) 2012-10-24 2014-05-01 The Procter & Gamble Company Anti foam compositions comprising partly phenyl bearing polyorganosilicons
US9095787B2 (en) 2012-10-24 2015-08-04 The Procter & Gamble Company Compositions comprising anti-foams
KR20150082502A (en) 2012-11-05 2015-07-15 다니스코 유에스 인크. Compositions and methods comprising thermolysin protease variants
US20140161741A1 (en) 2012-12-06 2014-06-12 The Procter & Gamble Company Perfume systems
US9303232B2 (en) 2012-12-06 2016-04-05 The Procter & Gamble Company Perfume systems
JP6461000B2 (en) 2012-12-14 2019-01-30 ザ プロクター アンド ギャンブル カンパニー Fragrance material
US20150344858A1 (en) 2012-12-19 2015-12-03 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
EP2964740B1 (en) 2013-03-05 2017-10-04 The Procter and Gamble Company Mixed sugar-based amide surfactant compositions
US9631164B2 (en) 2013-03-21 2017-04-25 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
US9340757B2 (en) 2013-04-18 2016-05-17 The Procter & Gamble Company Fragrance materials
AR096270A1 (en) 2013-05-14 2015-12-16 Novozymes As DETERGENT COMPOSITIONS
EP2806018A1 (en) 2013-05-20 2014-11-26 The Procter & Gamble Company Encapsulates
US20140338134A1 (en) 2013-05-20 2014-11-20 The Procter & Gamble Company Encapsulates
JP6077177B2 (en) 2013-05-28 2017-02-08 ザ プロクター アンド ギャンブル カンパニー Surface treatment composition containing photochromic dye
WO2014194032A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3004342B1 (en) 2013-05-29 2023-01-11 Danisco US Inc. Novel metalloproteases
DK3882346T3 (en) 2013-05-29 2025-12-22 Danisco Us Inc UNKNOWN METALLOPROTEASES
WO2014194034A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3019603A1 (en) 2013-07-09 2016-05-18 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
WO2015010009A2 (en) 2013-07-19 2015-01-22 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2015038792A1 (en) 2013-09-12 2015-03-19 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
WO2015042086A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care composition comprising carboxylate dye
MX2016003538A (en) 2013-09-18 2016-06-28 Procter & Gamble Laundry care compositions containing thiophene azo carboxylate dyes.
US9834682B2 (en) 2013-09-18 2017-12-05 Milliken & Company Laundry care composition comprising carboxylate dye
CN105555935A (en) 2013-09-18 2016-05-04 宝洁公司 Laundry care composition comprising carboxylate dye
US20160312204A1 (en) 2013-12-13 2016-10-27 Danisco Us Inc. Serine proteases of bacillus species
EP3080263B1 (en) 2013-12-13 2019-07-03 Danisco US Inc. Serine proteases of the bacillus gibsonii-clade
EP3097175B1 (en) 2014-01-22 2018-10-17 The Procter and Gamble Company Fabric treatment composition
EP3097172A1 (en) 2014-01-22 2016-11-30 The Procter & Gamble Company Method of treating textile fabrics
WO2015112340A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Method of treating textile fabrics
EP3097173B1 (en) 2014-01-22 2020-12-23 The Procter and Gamble Company Fabric treatment composition
US10208297B2 (en) 2014-01-22 2019-02-19 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same for cleaning
JP2017508848A (en) 2014-03-12 2017-03-30 ザ プロクター アンド ギャンブル カンパニー Detergent composition
US10155935B2 (en) 2014-03-12 2018-12-18 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
MX2016012044A (en) 2014-03-21 2017-06-29 Danisco Us Inc Serine proteases of bacillus species.
WO2015148743A1 (en) 2014-03-26 2015-10-01 The Procter & Gamble Company Perfume systems
CN106715465B (en) 2014-04-15 2021-10-08 诺维信公司 Polypeptides with lipase activity and polynucleotides encoding them
EP3140384B1 (en) 2014-05-06 2024-02-14 Milliken & Company Laundry care compositions
EP3139902A2 (en) 2014-05-06 2017-03-15 The Procter & Gamble Company Fragrance compositions
WO2015181118A1 (en) 2014-05-27 2015-12-03 Novozymes A/S Methods for producing lipases
EP3760713A3 (en) 2014-05-27 2021-03-31 Novozymes A/S Lipase variants and polynucleotides encoding same
EP3197511A1 (en) 2014-09-26 2017-08-02 The Procter & Gamble Company Personal care compositions comprising malodor reduction compositions
DK3207129T3 (en) 2014-10-17 2020-02-24 Danisco Us Inc SERIN PROTEAS OF THE BACILLUS ART
CN107148472A (en) 2014-10-27 2017-09-08 丹尼斯科美国公司 The serine protease of Bacillus spec
EP3212781B1 (en) 2014-10-27 2019-09-18 Danisco US Inc. Serine proteases
EP3212783B1 (en) 2014-10-27 2024-06-26 Danisco US Inc. Serine proteases
WO2016069569A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
DK3212662T3 (en) 2014-10-27 2020-07-20 Danisco Us Inc serine proteases
EP3256563A1 (en) 2014-11-17 2017-12-20 The Procter and Gamble Company Benefit agent delivery compositions
EP4067485A3 (en) 2014-12-05 2023-01-04 Novozymes A/S Lipase variants and polynucleotides encoding same
US20160230124A1 (en) 2015-02-10 2016-08-11 The Procter & Gamble Company Liquid laundry cleaning composition
US9499770B2 (en) 2015-03-10 2016-11-22 The Procter & Gamble Company Freshening compositions resisting scent habituation
DK3268471T3 (en) 2015-03-12 2019-12-02 Danisco Us Inc COMPOSITIONS AND METHODS OF COMPREHENSIVE LG12 CLADE PROTEASE VARIETIES
CN107624127A (en) 2015-04-29 2018-01-23 宝洁公司 Methods of Treating Fabrics
HUE043043T2 (en) 2015-04-29 2019-07-29 Procter & Gamble Method of treating a fabric
EP3088504B1 (en) 2015-04-29 2021-07-21 The Procter & Gamble Company Method of treating a fabric
WO2016176280A1 (en) 2015-04-29 2016-11-03 The Procter & Gamble Company Method of treating a fabric
EP3088506B1 (en) 2015-04-29 2018-05-23 The Procter and Gamble Company Detergent composition
WO2016178668A1 (en) 2015-05-04 2016-11-10 Milliken & Company Leuco triphenylmethane colorants as bluing agents in laundry care compositions
EP4219704A3 (en) 2015-05-13 2023-08-23 Danisco US Inc Aprl-clade protease variants and uses thereof
WO2016184944A1 (en) 2015-05-19 2016-11-24 Novozymes A/S Odor reduction
CN108012543B (en) 2015-06-16 2022-01-04 诺维信公司 Polypeptides having lipase activity and polynucleotides encoding same
JP7015695B2 (en) 2015-06-17 2022-02-03 ダニスコ・ユーエス・インク Bacillus gibsonii clade serine protease
WO2016205008A1 (en) 2015-06-19 2016-12-22 The Procter & Gamble Company Computer-implemeted method of making perfumed goods
CN107922930A (en) 2015-07-01 2018-04-17 诺维信公司 ways to reduce odor
CN107969136B (en) 2015-07-06 2021-12-21 诺维信公司 Lipase variants and polynucleotides encoding same
US9745544B2 (en) 2015-10-13 2017-08-29 The Procter & Gamble Company Whitening agents for cellulosic substrates
US9902923B2 (en) 2015-10-13 2018-02-27 The Procter & Gamble Company Polyglycerol dye whitening agents for cellulosic substrates
US10597614B2 (en) 2015-10-13 2020-03-24 The Procter & Gamble Company Whitening agents for cellulosic substrates
US9976035B2 (en) 2015-10-13 2018-05-22 Milliken & Company Whitening agents for cellulosic substrates
US10155868B2 (en) 2015-10-13 2018-12-18 Milliken & Company Whitening agents for cellulosic substrates
US9777250B2 (en) 2015-10-13 2017-10-03 Milliken & Company Whitening agents for cellulosic substrates
EP3371308B1 (en) 2015-11-05 2022-05-11 Danisco US Inc. Paenibacillus sp. mannanases
CN108603183B (en) 2015-11-05 2023-11-03 丹尼斯科美国公司 Paenibacillus spp. and Bacillus spp. mannanase
WO2017091674A1 (en) 2015-11-26 2017-06-01 The Procter & Gamble Company Liquid detergent compositions comprising protease and encapsulated lipase
CN108431217B (en) 2015-12-01 2022-06-21 诺维信公司 Method for producing lipase
US10308900B2 (en) 2015-12-22 2019-06-04 Milliken & Company Occult particles for use in granular laundry care compositions
WO2017165615A1 (en) 2016-03-24 2017-09-28 The Procter & Gamble Company Hair care compositions comprising malodor reduction compositions
BR112018072530A2 (en) 2016-05-03 2019-03-26 Danisco Us Inc protease variants and uses thereof
BR112018072586A2 (en) 2016-05-05 2019-02-19 Danisco Us Inc protease variants and uses thereof
CA3026064A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
CA3027745A1 (en) 2016-06-17 2017-12-21 Danisco Us Inc. Protease variants and uses thereof
EP3485008B1 (en) 2016-07-18 2024-01-31 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
US20180119056A1 (en) 2016-11-03 2018-05-03 Milliken & Company Leuco Triphenylmethane Colorants As Bluing Agents in Laundry Care Compositions
US10577571B2 (en) 2016-11-08 2020-03-03 Ecolab Usa Inc. Non-aqueous cleaner for vegetable oil soils
EP4520820A3 (en) 2016-12-21 2025-04-16 Danisco Us Inc Protease variants and uses thereof
US11946081B2 (en) 2016-12-21 2024-04-02 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
EP3583210B1 (en) 2017-03-15 2021-07-07 Danisco US Inc. Trypsin-like serine proteases and uses thereof
US11078445B2 (en) 2017-05-05 2021-08-03 Novozymes A/S Compositions comprising lipase and sulfite
JP7317811B2 (en) 2017-09-27 2023-07-31 ノボザイムス アクティーゼルスカブ Lipase variants and microcapsule compositions containing such lipase variants
CN111278416A (en) 2017-10-10 2020-06-12 宝洁公司 Sulfate-free personal cleansing compositions with low inorganic salts
EP3717643A1 (en) 2017-11-29 2020-10-07 Danisco US Inc. Subtilisin variants having improved stability
CN111670248A (en) 2017-12-04 2020-09-15 诺维信公司 Lipase variants and polynucleotides encoding the same
ES2955269T3 (en) 2017-12-08 2023-11-29 Novozymes As Alpha-amylase variants and polynucleotides that encode them
US10792384B2 (en) 2017-12-15 2020-10-06 The Procter & Gamble Company Rolled fibrous structures comprising encapsulated malodor reduction compositions
WO2019154952A1 (en) 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
EP3749761A1 (en) 2018-02-08 2020-12-16 Novozymes A/S Lipases, lipase variants and compositions thereof
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3799601A1 (en) 2018-06-19 2021-04-07 Danisco US Inc. Subtilisin variants
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
EP3844255A1 (en) 2018-08-30 2021-07-07 Danisco US Inc. Enzyme-containing granules
JP2022503923A (en) 2018-09-27 2022-01-12 ダニスコ・ユーエス・インク Composition for cleaning medical equipment
US20200123319A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
US20200123475A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
US11466122B2 (en) 2018-10-18 2022-10-11 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US20200123472A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
US11299591B2 (en) 2018-10-18 2022-04-12 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US11518963B2 (en) 2018-10-18 2022-12-06 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US11732218B2 (en) 2018-10-18 2023-08-22 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
EP3887515A1 (en) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin variants having improved stability
CN114174504B (en) 2019-05-24 2026-04-17 丹尼斯科美国公司 Subtilis protease variants and usage methods
EP3994255A1 (en) 2019-07-02 2022-05-11 Novozymes A/S Lipase variants and compositions thereof
US11873465B2 (en) 2019-08-14 2024-01-16 Ecolab Usa Inc. Methods of cleaning and soil release of highly oil absorbing substrates employing optimized extended chain nonionic surfactants
EP4022020A1 (en) 2019-08-27 2022-07-06 Novozymes A/S Composition comprising a lipase
CN114746153A (en) 2019-12-06 2022-07-12 宝洁公司 Sulfate-free compositions with enhanced scalp active deposition
US20230049452A1 (en) 2020-01-13 2023-02-16 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
CN115151310B (en) 2020-02-27 2024-12-20 宝洁公司 Sulfur-containing anti-dandruff compositions with enhanced efficacy and aesthetics
US12031113B2 (en) 2020-03-02 2024-07-09 Milliken & Company Composition comprising hueing agent
US12195703B2 (en) 2020-03-02 2025-01-14 Milliken & Company Composition comprising hueing agent
US11718814B2 (en) 2020-03-02 2023-08-08 Milliken & Company Composition comprising hueing agent
EP4176031A1 (en) 2020-07-06 2023-05-10 Ecolab USA Inc. Peg-modified castor oil based compositions for microemulsifying and removing multiple oily soils
CA3185062A1 (en) 2020-07-06 2022-01-13 Gang Pu Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane
CN116075583A (en) 2020-07-06 2023-05-05 埃科莱布美国股份有限公司 Foaming mixed alcohol/water compositions comprising a combination of an alkylsiloxane and a hydrotrope/solubilizer
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN116323893A (en) 2020-10-16 2023-06-23 宝洁公司 Consumer product composition comprising population of encapsulates
US12227720B2 (en) 2020-10-16 2025-02-18 The Procter & Gamble Company Consumer product compositions with at least two encapsulate populations
BR112023008326A2 (en) 2020-10-29 2023-12-12 Novozymes As LIPASE VARIANTS AND COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS
CN116670261A (en) 2020-11-13 2023-08-29 诺维信公司 Detergent composition comprising lipase
CA3198853A1 (en) 2020-11-23 2022-05-27 The Procter & Gamble Company Personal care compositions free of sulfated surfactants
MX2023005963A (en) 2020-12-04 2023-06-07 Procter & Gamble Hair care compositions comprising malodor reduction materials.
WO2022197295A1 (en) 2021-03-17 2022-09-22 Milliken & Company Polymeric colorants with reduced staining
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
WO2023017794A1 (en) 2021-08-10 2023-02-16 株式会社日本触媒 Polyalkylene-oxide-containing compound
EP4402258A2 (en) 2021-09-13 2024-07-24 Danisco US Inc. Bioactive-containing granules
CA3235522A1 (en) 2021-12-09 2023-06-15 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation
EP4448751A2 (en) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisin variants and methods of use
EP4448750A2 (en) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisin variants and uses thereof
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
CN118871559A (en) 2021-12-21 2024-10-29 诺维信公司 Composition comprising lipase and a enhancer
EP4544015A2 (en) 2022-06-24 2025-04-30 Novozymes A/S Lipase variants and compositions comprising such lipase variants
WO2024020445A1 (en) 2022-07-20 2024-01-25 Ecolab Usa Inc. Novel nonionic extended surfactants, compositions and methods of use thereof
EP4581137A1 (en) 2022-09-02 2025-07-09 Danisco Us Inc Mannanase variants and methods of use
CN120112635A (en) 2022-09-02 2025-06-06 丹尼斯科美国公司 Subtilisin variants and methods related thereto
EP4581119A1 (en) 2022-09-02 2025-07-09 Danisco US Inc. Detergent compositions and methods related thereto
CN120303400A (en) 2022-11-09 2025-07-11 丹尼斯科美国公司 Subtilisin variants and methods of use
CN120225643A (en) 2022-12-05 2025-06-27 诺维信公司 Compositions comprising lipase and peptide
WO2024163584A1 (en) 2023-02-01 2024-08-08 Danisco Us Inc. Subtilisin variants and methods of use
EP4677080A1 (en) 2023-03-06 2026-01-14 Danisco US Inc. Subtilisin variants and methods of use
WO2025085351A1 (en) 2023-10-20 2025-04-24 Danisco Us Inc. Subtilisin variants and methods of use
WO2025133314A1 (en) 2023-12-21 2025-06-26 Heubach Holding Switzerland Ag (Ltd) Polymeric dyes with enhanced biodegradability containing polycarboxylic acids, amino acids, polyamino acids and/or peptide building blocks
EP4617327A1 (en) 2024-03-13 2025-09-17 Heubach Holding Switzerland AG (Ltd) Polymeric dyes with enhanced biodegradability containing saccharide or polysaccharide building blocks
WO2026024921A1 (en) 2024-07-25 2026-01-29 The Procter & Gamble Company Detergent composition comprising a subtilisin variant and methods of use
WO2026050315A1 (en) 2024-08-29 2026-03-05 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263759C (en) * 1997-03-07 2006-07-12 宝洁公司 Improving method for preparing cross-bridge macrocylic compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. R. WEISMAN ET AL: "Cross-bridged protonation and Li+ complexation in diamond-lattice cleft", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 112, no. 23, 1990, DC US, pages 8604 - 8605, XP002066456 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940402A3 (en) * 1998-03-05 2002-07-10 Clariant GmbH Quaternary polycyclic polyammonium salts and process for their preparation
WO2000029413A1 (en) * 1998-11-13 2000-05-25 The Procter & Gamble Company Process for preparing cross-bridged tetraaza macrocycles
WO2000029537A1 (en) * 1998-11-13 2000-05-25 The Procter & Gamble Company Bleach compositions
US6555681B1 (en) 1998-11-13 2003-04-29 Procter & Gamble Company Process for preparing cross-bridged tetraaza macrocycles
US6667288B2 (en) 1998-11-13 2003-12-23 Procter & Gamble Company Bleach compositions
WO2000032601A3 (en) * 1998-11-30 2000-10-05 Procter & Gamble Process for preparing cross-bridged tetraaza macrocycles
WO2002026267A3 (en) * 2000-09-25 2003-04-03 Procter & Gamble Manganes complexes for magnetic resonance imaging
US6627176B2 (en) * 2000-09-25 2003-09-30 Procter & Gamble Company Metal complexes for use in medical and therapeutic applications
US8034800B2 (en) 2004-06-10 2011-10-11 University Of Hull Antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
DE102011010818A1 (en) 2011-02-10 2012-08-16 Clariant International Ltd. Use of transition metal complexes as bleaching catalysts in detergents and cleaners
WO2012107187A1 (en) 2011-02-10 2012-08-16 Clariant International Ltd Use of transition metal complexes as bleach catalysts in washing and cleaning compositions
US9102903B2 (en) 2011-02-10 2015-08-11 Weylchem Switzerland Ag Use of transition metal complexes as bleach catalysts in washing and cleaning compositions

Also Published As

Publication number Publication date
BR9808657A (en) 2000-05-23
CN1495185A (en) 2004-05-12
CN1134443C (en) 2004-01-14
EP0971927A1 (en) 2000-01-19
CN1263759C (en) 2006-07-12
EP0971927B1 (en) 2005-06-15
CA2282477C (en) 2004-11-30
US20020007057A1 (en) 2002-01-17
CN1255134A (en) 2000-05-31
US6225464B1 (en) 2001-05-01
AU6226198A (en) 1998-09-22
ES2245020T3 (en) 2005-12-16
US6444808B2 (en) 2002-09-03
CN1434049A (en) 2003-08-06
ATE297928T1 (en) 2005-07-15
CN1250558C (en) 2006-04-12
DE69830574D1 (en) 2005-07-21
JP4376320B2 (en) 2009-12-02
JP2001513816A (en) 2001-09-04
CA2282477A1 (en) 1998-09-11
CA2448261A1 (en) 1998-09-11
DE69830574T2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
EP0971927B1 (en) Improved methods of making cross-bridged macropolycycles
US4892941A (en) Porphyrins
US5274147A (en) Process for preparing manganese complexes
WO1994005422A1 (en) Synthesis of manganese bleach catalyst
WO1993025562A1 (en) Synthesis of manganese oxidation catalyst
JPS6230122B2 (en)
Yamada et al. Oxidation of allylic alcohols, amines, and sulfides mediated by assembled triphase catalyst of phosphotungstate and non-cross-linked amphiphilic copolymer
EP0532326B1 (en) Nitrated metalloporphyrins as catalysts for alkane oxidation
Chavan et al. Selective oxidation of para-xylene to terephthalic acid by μ3-oxo-bridged Co/Mn cluster complexes encapsulated in zeolite–Y
EP0363379B1 (en) Porphyrins, their syntheses and uses thereof
Anjali et al. Copper based macromolecular catalysts for the hydroxylation of phenols
CA2139177A1 (en) Porphyrins and their synthesis from dipyrromethanes and aldehydes
EP0665056A2 (en) Method for oxidizing alkanes using halocarbyl-substituted porphyrins synthesized from meso-halocarbyl-dipyrromethanes and aldehydes
WO2013123513A1 (en) Use of metalloporphyrins and salen complexes for the catalytic oxidation of organic compounds
Shah et al. Catalytic efficiency and kinetic analysis of manganese polyoxometalate heterogenized in MIL-100-Fe for selective Olefin oxidation using H2O2
US4271033A (en) Transition metal complex catalysts
US20020173644A1 (en) Methods of making cross-bridged macropolycycles
EP1129095B1 (en) Process for preparing cross-bridged tetraaza macrocycles
MXPA99008246A (en) Improved methods of making cross-bridged macropolycycles
JP2845982B2 (en) Fluorinated porphyrin compounds
US6307100B1 (en) Catalytic oxidation of hydrocarbons
Ellis Jr et al. Novel biphasic synthesis of porphyrin
US4845245A (en) Process for producing 3,3-bis-(4-dimethylaminophenyl)-6-dimethylaminophthalide
JPH03279347A (en) Method for purifying 4,4'-diphenyldicarboxylic acid
Mapoliea et al. INDUSTRIAL WASTEWATER REMEDIATION VIA WET-AIR OXIDATION USING IMMOBILISED TRANSITION METAL CATALYSTS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804833.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2282477

Country of ref document: CA

Ref document number: 2282477

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1998 538311

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008246

Country of ref document: MX

Ref document number: 09380675

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998904331

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998904331

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1998904331

Country of ref document: EP